1
|
Bye AP, Kriek N, Sage T, Rawlings SJ, Prodger C, Kesavan M, Lees C, Booth S, Cowen LG, Shefferd K, Desborough MJ, Gibbins JM, Eyre TA. Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib. Haematologica 2023; 108:1429-1435. [PMID: 36519322 PMCID: PMC10153540 DOI: 10.3324/haematol.2022.281402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2022] [Accepted: 12/05/2022] [Indexed: 12/23/2022] Open
Affiliation(s)
- Alexander P Bye
- Molecular and Clinical Sciences Research Institute, St George's University, Cranmer Terrace, London, United Kingdom; Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, RG6 6EX.
| | - Neline Kriek
- Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, RG6 6EX
| | - Tanya Sage
- Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, RG6 6EX
| | - Suzannah J Rawlings
- Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading,
| | - Catherine Prodger
- Department of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE
| | - Murali Kesavan
- Department of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE
| | - Charlotte Lees
- Department of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE
| | - Stephen Booth
- Department of Clinical Haematology, Royal Berkshire Hospital NHS Foundation Trust, Reading, RG1 5AN
| | - Louise G Cowen
- Haematology Late Phase Clinical Trial Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE
| | - Kirsty Shefferd
- Haematology Late Phase Clinical Trial Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE
| | - Michael J Desborough
- Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE
| | - Jonathan M Gibbins
- Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, RG6 6EX
| | - Toby A Eyre
- Department of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford,
| |
Collapse
|
2
|
Ashraf M, AlShammari A, De Sousa P, Naruka V, Tincknell L, Booth S, Proli C, Patel A, Docherty C, Murray J, Wagner T, Mhizha N, Lim E. EP01.07-006 Incidence and Resource Burden for the Management of CT Detected Ground Glass Opacities at a Tertiary Lung Cancer Service in the UK. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
3
|
Steffanoni S, Calimeri T, Laurenge A, Fox CP, Soussain C, Grommes C, Tisi MC, Boot J, Crosbie N, Visco C, Arcaini L, Chaganti S, Sassone MC, Alencar A, Armiento D, Romano I, Dietrich J, Itchaki G, Bruna R, Fracchiolla NS, Arletti L, Venditti A, Booth S, Musto P, Hoang Xuan K, Batchelor T, Cwynarski K, Ferreri AJM. Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group. Br J Haematol 2022; 199:507-519. [PMID: 35945164 PMCID: PMC9538907 DOI: 10.1111/bjh.18396] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Revised: 07/18/2022] [Accepted: 07/22/2022] [Indexed: 01/19/2023]
Abstract
To optimise management of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection identifying high-risk patients and maintaining treatment dose intensity is an important issue in patients with aggressive lymphomas. In the present study, we report on the presentation, management, and outcome of an international series of 91 patients with primary central nervous system lymphoma and SARS-CoV-2 infection. SARS-CoV-2 was diagnosed before/during first-line treatment in 64 patients, during follow-up in 21, and during salvage therapy in six. Among the 64 patients infected before/during first-line chemotherapy, 38 (59%) developed pneumonia and 26 (41%) did not clear the virus. Prolonged exposure to steroids before viral infection and/or treatment with high-dose cytarabine favoured pneumonia development and virus persistence and were associated with poorer survival; 81% of patients who did not clear virus died early from coronavirus disease 2019 (COVID-19). Vaccination was associated with lower pneumonia incidence and in-hospital mortality. Chemotherapy was initiated/resumed in 43 (67%) patients, more commonly among patients who did not develop pneumonia, cleared the virus, or did not receive steroids during infection. Chemotherapy resumption in patients with viral persistence should be indicated cautiously as it was associated with a poorer survival (6-month, 70% and 87%, p = 0.07). None of the 21 patients infected during follow-up died from COVID-19, requiring similar measures as infected subjects in the general population.
Collapse
Affiliation(s)
- Sara Steffanoni
- Lymphoma Unit, Department of Onco‐HematologyIRCCS San Raffaele Scientific InstituteMilanItaly
| | - Teresa Calimeri
- Lymphoma Unit, Department of Onco‐HematologyIRCCS San Raffaele Scientific InstituteMilanItaly
| | - Alice Laurenge
- Service de Neurologie 2‐MazarinHôpitaux Universitaires La Pitié Salpêtrière, APHP, Sorbonne UniversitéParisFrance
| | | | - Carole Soussain
- Hôpital René Huguenin‐Institut Curie, Saint‐CloudParisFrance
| | - Christian Grommes
- Department of NeurologyMemorial Sloan Kettering Cancer CenterNew YorkNew YorkUSA
| | | | - Jesca Boot
- BarkingHavering and Redbridge University Hospitals NHS TrustLondonUK
| | | | - Carlo Visco
- Department of Medicine, Section of HematologyUniversity of VeronaVeronaItaly
| | - Luca Arcaini
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo and Department of Molecular MedicineUniversity of PaviaPaviaItaly
| | | | - Marianna C. Sassone
- Lymphoma Unit, Department of Onco‐HematologyIRCCS San Raffaele Scientific InstituteMilanItaly
| | - Alvaro Alencar
- Department of Hematology and OncologyUniversity of Miami/Sylvester Comprehensive Cancer CenterMiamiFloridaUSA
| | | | | | - Jorg Dietrich
- Division of Neuro‐OncologyMassachusetts General Hospital Cancer CenterBostonMassachusettsUSA
| | - Gilad Itchaki
- Institute of Hematology, Davidoff Cancer Center, Rabin Medical CenterPetah‐TikvaIsrael
| | | | | | - Laura Arletti
- Division of HematologyAzienda USL‐IRCCS of Reggio EmiliaReggio EmiliaItaly
| | - Adriano Venditti
- Department of Biomedicine and PreventionUniversity Tor VergataRomeItaly
| | - Stephen Booth
- NIHR Oxford Biomedical Research CentreChurchill HospitalOxfordUK
| | - Pellegrino Musto
- Department of Emergency and Organ Transplantation‘Aldo Moro’ University School of Medicine, and Unit of Hematology and Stem Cell Transplantation, AOUC PoliclinicoBariItaly
| | - Khê Hoang Xuan
- Service de Neurologie 2‐MazarinHôpitaux Universitaires La Pitié Salpêtrière, APHP, Sorbonne UniversitéParisFrance
| | - Tracy T. Batchelor
- Department of NeurologyBrigham and Women’s HospitalBostonMassachusettsUSA
| | - Kate Cwynarski
- Department of HaematologyUniversity College London HospitalLondonUK
| | - Andrés J. M. Ferreri
- Lymphoma Unit, Department of Onco‐HematologyIRCCS San Raffaele Scientific InstituteMilanItaly
| |
Collapse
|
4
|
Booth S, Desborough M, Curry N, Stanworth S. Platelet transfusion and anticoagulation in hematological cancer-associated thrombosis and thrombocytopenia: The CAVEaT multicenter prospective cohort. J Thromb Haemost 2022; 20:1830-1838. [PMID: 35505495 DOI: 10.1111/jth.15748] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2022] [Revised: 04/14/2022] [Accepted: 04/21/2022] [Indexed: 11/29/2022]
Abstract
BACKGROUND Venous thromboembolism (VTE) in patients with thrombocytopenia represents a complex management challenge. OBJECTIVES To describe practice, document outcomes, and compare management to national guidelines. METHODS We present a prospective multicenter cohort of 105 patients with hematological cancer, VTE within 28 days, and platelets <50 × 109 /L from May 14, 2019 to April 24, 2021 from 20 sites. RESULTS Median age was 64 and median initial platelet count 28 × 109 /L. Thromboses were: 46% catheter-associated, 11% lower limb, 33% pulmonary emboli (PE), and 10% other sites. Management was according to International Society on Thrombosis and Haemostasis (ISTH) guidance in 30 (47%) of 64 patients with high-risk thrombosis and 2 (5%) of low-risk thrombosis (catheter-associated or asymptomatic subsegmental PE). Twelve patients (11%) received no anticoagulation. At 28 days mortality was 15%, 8% experienced VTE progression, 7% experienced major bleeding, and 25% experienced clinically relevant non-major bleeding. Four inferior vena cava filters were placed, two were later removed. The median number of platelet units transfused was 5 (range 0-53). Twenty-seven percent of patients had a change of management strategy by 28 days. There was no clear relationship among platelet transfusion threshold, anticoagulant dose reduction threshold, and risk of thrombosis progression or major bleeding. CONCLUSIONS This data set demonstrates the heterogeneity of approaches used in patients presenting with severe thrombocytopenia and acute thrombosis and confirms the high rates of bleeding in this cohort with thrombosis progression rates similar to the wider cancer-associated thrombosis population. Randomized data is required to inform the optimal management.
Collapse
Affiliation(s)
- Stephen Booth
- Department of Clinical Haematology, Royal Berkshire Hospital NHS Foundation Trust, Reading, UK
| | | | - Nicola Curry
- Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Simon Stanworth
- NHS Blood and Transplant, Oxford, UK
- Radcliffe Department of Medicine, University of Oxford, Oxford, UK
| |
Collapse
|
5
|
Marchesi F, Salmanton-García J, Emarah Z, Piukovics K, Nucci M, López-García A, Rácil Z, Farina F, Popova M, Zompi S, Audisio E, Ledoux MP, Verga L, Weinbergerová B, Szotkovski T, Da Silva MG, Fracchiolla N, De Jonge N, Collins G, Marchetti M, Magliano G, García-Vidal C, Biernat MM, Van Doesum J, Machado M, Demirkan F, Al-Khabori M, Žák P, Víšek B, Stoma I, Méndez GA, Maertens J, Khanna N, Espigado I, Dragonetti G, Fianchi L, Del Principe MI, Cabirta A, Ormazabal-Vélez I, Jaksic O, Buquicchio C, Bonuomo V, Batinié J, Omrani AS, Lamure S, Finizio O, Fernández N, Falces-Romero I, Blennow O, Bergantim R, Ali N, Win S, Van Praet J, Tisi MC, Shirinova A, Schönlein M, Prattes J, Piedimonte M, Petzer V, Navrátil M, Kulasekararaj A, Jindra P, Sramek J, Glenthøj A, Fazzi R, De Ramón-Sánchez C, Cattaneo C, Calbacho M, Bahr NC, El-Ashwah S, Cordoba R, Hanakova M, Zambrotta GPM, Zambrotta G, Sciumè M, Booth S, Rodrigues RN, Sacchi MV, García-Poutón N, Martín-González JA, Khostelidi S, Gräfe S, Rahimli L, Ammatuna E, Busca A, Corradini P, Hoenigl M, Klimko N, Koehler P, Pagliuca A, Passamonti F, Cornely OA, Pagano L. COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA). Haematologica 2022; 108:22-33. [PMID: 35545919 PMCID: PMC9827164 DOI: 10.3324/haematol.2022.280847] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2022] [Indexed: 02/04/2023] Open
Abstract
Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients diagnosed with COVID-19 between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the preceding 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with better survival when AML treatment could be delayed (80%; P<0.001). Overall survival in patients with a diagnosis of COVID-19 between January 2020 and August 2020 was significantly lower than that in patients diagnosed between September 2020 and February 2021 and between March 2021 and September 2021 (39.8% vs. 60% vs. 61.9%, respectively; P=0.006). COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment, whenever possible.
Collapse
Affiliation(s)
- Francesco Marchesi
- Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy,FM and JSG contributed equally as co-first authors
| | - Jon Salmanton-García
- University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany,University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Cologne, Germany,FM and JSG contributed equally as co-first authors
| | - Ziad Emarah
- Oncology Center, Mansoura University, Mansoura, Egypt
| | - Klára Piukovics
- Department of Internal Medicine, South Division Faculty of Medicine University of Szeged, Szeged, Hungary
| | - Marcio Nucci
- Department of Internal Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
| | - Alberto López-García
- Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain
| | - Zdenék Rácil
- Institute of Hematology and Blood Transfusion, Prague, Czech Republic
| | | | - Marina Popova
- RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russia
| | - Sofia Zompi
- Stem Cell Transplant Center, AOU Citta' della Salute e della Scienza, Turin, Italy
| | - Ernesta Audisio
- Stem Cell Transplant Center, AOU Citta' della Salute e della Scienza, Turin, Italy
| | | | - Luisa Verga
- Azienda Ospedaliera San Gerardo - Monza, Monza, Italy,Università Milano-Bicocca, Milan, Italy
| | - Barbora Weinbergerová
- Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
| | | | | | - Nicola Fracchiolla
- Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Nick De Jonge
- Amsterdam UMC, location VUmc, Amsterdam, the Netherlands
| | | | - Monia Marchetti
- Azienda Ospedaliera Nazionale “SS. Antonio e Biagio e Cesare Arrigo”, Alessandria, Italy
| | | | - Carolina García-Vidal
- Department of Infectious Diseases, Hospital Clinic de Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain
| | - Monika M. Biernat
- Department of Haematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland
| | - Jaap Van Doesum
- University Medical Center Groningen, Groningen, the Netherlands
| | - Marina Machado
- Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Fatih Demirkan
- Division of Hematology, Dokuz Eylul University, Izmir, Turkey
| | | | - Pavel Žák
- University Hospital Hradec Králové, Hradec Králové, Czech Republic
| | - Benjamín Víšek
- University Hospital Hradec Králové, Hradec Králové, Czech Republic
| | - Igor Stoma
- Gomel State Medical University, Gomel, Belarus
| | | | - Johan Maertens
- Department of Microbiology, Immunology, and Transplantation, KULeuven and Department of Hematology, UZ Leuven, Leuven, Belgium
| | - Nina Khanna
- Division of Infectious Diseases and Hospital Epidemiology, and Department of Clinical Research, University and University Hospital of Basel, Basel, Switzerland
| | - Ildefonso Espigado
- Department of Hematology, University Hospital Virgen Macarena - University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC), Universidad de Sevilla, Seville, Spain
| | - Giulia Dragonetti
- Hematology Unit, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS, Rome, Italy
| | - Luana Fianchi
- Hematology Unit, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS, Rome, Italy
| | | | - Alba Cabirta
- Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain,Department of Hematology, Vall d’Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
| | | | | | | | - Valentina Bonuomo
- Department of Medicine, Section of Hematology, University of Verona, Verona, Italy
| | - Josip Batinié
- Croatian Cooperative Group for Hematological Diseases (CROHEM), Zagreb, Croatia,Faculty of Medicine University of Zagreb, Zagreb, Croatia,University Hospital Centre Zagreb, Zagreb, Croatia
| | - Ali S. Omrani
- Hamad Medical Corporation, Division of Infectious Diseases, Doha, Qatar
| | - Sylvain Lamure
- Département d’Hématologie Clinique, CHU de Montpellier, UMR-CNRS 5535, Universite de Montpellier, Montpellier, France
| | | | - Noemí Fernández
- Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | | | - Ola Blennow
- Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
| | - Rui Bergantim
- Centro Hospitalar e Universitário São João, Porto, Portugal
| | - Natasha Ali
- Aga Khan University Hospital, Karachi, Pakistan
| | - Sein Win
- Department of Clinical Hematology, Yangon General Hospital, University of Medicine, Yangon, Myanmar
| | - Jens Van Praet
- Department of Nephrology and Infectious Diseases, AZ Sint-Jan Brugge-Oostende AV, Brugge, Belgium
| | | | - Ayten Shirinova
- Azerbaijan Scientific Research Hematology and Transfusiology Institute, Baku, Azerbaijan
| | - Martin Schönlein
- Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Juergen Prattes
- Medical University of Graz, Department for Infectious Diseases, Graz, Austria
| | | | - Verena Petzer
- Department of Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria
| | - Milan Navrátil
- Head of the ICU and Transplant Unit, Department of Hematooncology, University Hospital of Ostrava, Ostrava-Poruba, Czech Republic
| | | | - Pavel Jindra
- University Hospital Pilsen, Pilsen, Czech Republic
| | - Jirí Sramek
- Department of Hematology and Oncology, University Hospital Pilsen, Pilsen, Czech Republic,Department of Histology and Embryology, Faculty of Medicine, Pilsen, Czech Republic
| | - Andreas Glenthøj
- Department of Hematology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
| | - Rita Fazzi
- AOUP - Azienda Ospedaliera Università Pisana - Cisanello, Pisa, Italy
| | - Cristina De Ramón-Sánchez
- Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain,IBSAL, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain
| | | | | | | | | | - Raul Cordoba
- Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain
| | - Michaela Hanakova
- Institute of Hematology and Blood Transfusion, Prague, Czech Republic
| | | | | | - Mariarita Sciumè
- Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | | | | | - Maria Vittoria Sacchi
- Azienda Ospedaliera Nazionale “SS. Antonio e Biagio e Cesare Arrigo”, Alessandria, Italy
| | - Nicole García-Poutón
- Department of Infectious Diseases, Hospital Clinic de Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain
| | | | - Sofya Khostelidi
- North-Western State Medical University named after Iliá Ilich Méchnikov, Saint-Petersburg, Russia
| | - Stefanie Gräfe
- University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany,University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Cologne, Germany,Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany
| | - Laman Rahimli
- University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany,University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Cologne, Germany
| | | | - Alessandro Busca
- Stem Cell Transplant Center, AOU Citta' della Salute e della Scienza, Turin, Italy
| | - Paolo Corradini
- University of Milan and Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Martin Hoenigl
- Clinical and Translational Fungal-Working Group, University of California San Diego, La Jolla, CA, USA,Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, CA, USA,Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Graz, Austria
| | - Nikolai Klimko
- North-Western State Medical University named after Iliá Ilich Méchnikov, Saint-Petersburg, Russia
| | - Philipp Koehler
- University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany,University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Cologne, Germany
| | - Antonio Pagliuca
- Department of Haematological Medicine, Kings College Hospital NHS Foundation Trust, London, UK
| | - Francesco Passamonti
- Department of Medicine and Surgery, University of Insubria and ASST Sette Laghi, Ospedale di Circolo of Varese, Varese, Italy
| | - Oliver A. Cornely
- University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany,University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Cologne, Germany,German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany,University of Cologne, Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Köln), Cologne, Germany,OAC and LP contributed equally as co-senior authors
| | - Livio Pagano
- Hematology Unit, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS, Rome, Italy,Hematology Unit, Università Cattolica del Sacro Cuore, Rome, Italy,OAC and LP contributed equally as co-senior authors
| |
Collapse
|
6
|
Higgins H, Andrews N, Stowe J, Amirthalingam G, Ramsay M, Bahra G, Hackett A, Breen KA, Desborough M, Khan D, Leary H, Sweeney C, Hutchinson E, Shapiro SE, Lees C, Dhanapal J, MacCallum PK, Burke S, McDonald V, Entwistle NMA, Booth S, Atchison CJ, Hunt BJ. Risk of thrombosis with thrombocytopenia syndrome after COVID‐19 vaccination prior to the recognition of vaccine‐induced thrombocytopenia and thrombosis: A self‐controlled case series study in England. Res Pract Thromb Haemost 2022; 6:e12698. [PMID: 35475292 PMCID: PMC9020167 DOI: 10.1002/rth2.12698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2022] [Revised: 03/09/2022] [Accepted: 03/23/2022] [Indexed: 11/08/2022] Open
Abstract
Background Objectives Methods Results Conclusions
Collapse
Affiliation(s)
- Hannah Higgins
- Health Protection Division UK Health Security Agency London UK
| | - Nick Andrews
- Immunisation and Vaccine Preventable Diseases Division UK Health Security Agency London UK
| | - Julia Stowe
- Immunisation and Vaccine Preventable Diseases Division UK Health Security Agency London UK
| | - Gayatri Amirthalingam
- Immunisation and Vaccine Preventable Diseases Division UK Health Security Agency London UK
| | - Mary Ramsay
- Immunisation and Vaccine Preventable Diseases Division UK Health Security Agency London UK
| | - Gurpreet Bahra
- Centre for Thrombosis and Haemostasis St Thomas' Hospital Guy’s and Saint Thomas’ NHS Foundation Trust London UK
| | - Anthony Hackett
- Centre for Thrombosis and Haemostasis St Thomas' Hospital Guy’s and Saint Thomas’ NHS Foundation Trust London UK
| | - Karen A. Breen
- Centre for Thrombosis and Haemostasis St Thomas' Hospital Guy’s and Saint Thomas’ NHS Foundation Trust London UK
| | - Michael Desborough
- Oxford University Hospitals NHS Foundation Trust Oxford NIHR Biomedical Research Centre Oxford UK
- Radcliffe Department of Medicine University of Oxford Oxford UK
| | - Dalia Khan
- Oxford University Hospitals NHS Foundation Trust Oxford NIHR Biomedical Research Centre Oxford UK
- Radcliffe Department of Medicine University of Oxford Oxford UK
| | - Heather Leary
- Oxford University Hospitals NHS Foundation Trust Oxford NIHR Biomedical Research Centre Oxford UK
- Radcliffe Department of Medicine University of Oxford Oxford UK
| | - Connor Sweeney
- Oxford University Hospitals NHS Foundation Trust Oxford NIHR Biomedical Research Centre Oxford UK
- Radcliffe Department of Medicine University of Oxford Oxford UK
| | - Elizabeth Hutchinson
- Oxford University Hospitals NHS Foundation Trust Oxford NIHR Biomedical Research Centre Oxford UK
- Radcliffe Department of Medicine University of Oxford Oxford UK
| | - Susan E. Shapiro
- Oxford University Hospitals NHS Foundation Trust Oxford NIHR Biomedical Research Centre Oxford UK
- Radcliffe Department of Medicine University of Oxford Oxford UK
| | - Charlotte Lees
- Oxford University Hospitals NHS Foundation Trust Oxford NIHR Biomedical Research Centre Oxford UK
- Radcliffe Department of Medicine University of Oxford Oxford UK
| | - Jay Dhanapal
- Oxford University Hospitals NHS Foundation Trust Oxford NIHR Biomedical Research Centre Oxford UK
| | - Peter K. MacCallum
- Wolfson Institute of Population Health Queen Mary University of London London UK
- Barts Health NHS Trust London UK
| | | | | | | | - Stephen Booth
- Department of Haematology Royal Berkshire Hospital NHS Foundation Trust London UK
| | - Christina J. Atchison
- Patient Experience Research Centre School of Public Health Imperial College London London UK
| | - Beverley J. Hunt
- Centre for Thrombosis and Haemostasis St Thomas' Hospital Guy’s and Saint Thomas’ NHS Foundation Trust London UK
| |
Collapse
|
7
|
Eyre TA, Jensen P, Booth S, El-Galaly TC. Bone health and glucocorticoid-containing lymphoma therapy - a review of risk factors and preventative measures. Br J Haematol 2022; 198:431-442. [PMID: 35235226 DOI: 10.1111/bjh.18104] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Revised: 02/07/2022] [Accepted: 02/09/2022] [Indexed: 01/20/2023]
Abstract
With survival outcomes ever improving for patients with a wide range of lymphoma histologies, the focus on reducing long-term complications of therapy has increased. Recently published, complimentary population and retrospective series have highlighted the importance of considering bone health in patients treated for lymphoma. Fracture-related events or the requirement for secondary bone prophylaxis, likely linked to glucocorticoid-induced osteoporosis (GIO) are substantial and clinically meaningful in a significant minority of patients following routinely employed steroid-containing immunochemotherapy. In this review, we describe the pathophysiology of GIO, the risk of GIO in observational front-line lymphoma studies and efficacy of prophylactic measures from several prospective clinical trials are summarized. Finally, areas of importance for future research are discussed and recommendations for GIO risk assessment and management in lymphoma are provided based on the current available literature.
Collapse
Affiliation(s)
- Toby A Eyre
- Department of Haematology, Haematology and Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Paw Jensen
- Department of Haematology, Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark
| | - Stephen Booth
- Department of Haematology, Royal Berkshire Hospital NHS Foundation Trust, Reading, UK
| | - Tarec Christoffer El-Galaly
- Department of Haematology, Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark.,Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| |
Collapse
|
8
|
Booth S, Curley HM, Varnai C, Arnold R, Lee LYW, Campton NA, Cook G, Purshouse K, Aries J, Innes A, Cook LB, Tomkins O, Oram HS, Tilby M, Kulasekararaj A, Wrench D, Dolly S, Newsom‐Davies T, Pettengell R, Gault A, Moody S, Mittal S, Altohami M, Tillet T, Illingworth J, Mukherjee L, Apperly J, Ashcroft J, Rabin N, Carmichael J, Cazier J, Kerr R, Middleton G, Collins GP, Palles C. Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy. Br J Haematol 2022; 196:892-901. [PMID: 34761389 PMCID: PMC8652610 DOI: 10.1111/bjh.17937] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2021] [Revised: 10/19/2021] [Accepted: 10/20/2021] [Indexed: 12/13/2022]
Abstract
Patients with haematological malignancies have a high risk of severe infection and death from SARS-CoV-2. In this prospective observational study, we investigated the impact of cancer type, disease activity, and treatment in 877 unvaccinated UK patients with SARS-CoV-2 infection and active haematological cancer. The primary end-point was all-cause mortality. In a multivariate analysis adjusted for age, sex and comorbidities, the highest mortality was in patients with acute leukaemia [odds ratio (OR) = 1·73, 95% confidence interval (CI) 1·1-2·72, P = 0·017] and myeloma (OR 1·3, 95% CI 0·96-1·76, P = 0·08). Having uncontrolled cancer (newly diagnosed awaiting treatment as well as relapsed or progressive disease) was associated with increased mortality risk (OR = 2·45, 95% CI 1·09-5·5, P = 0·03), as was receiving second or beyond line of treatment (OR = 1·7, 95% CI 1·08-2·67, P = 0·023). We found no association between recent cytotoxic chemotherapy or anti-CD19/anti-CD20 treatment and increased risk of death within the limitations of the cohort size. Therefore, disease control is an important factor predicting mortality in the context of SARS-CoV-2 infection alongside the possible risks of therapies such as cytotoxic treatment or anti-CD19/anti-CD20 treatments.
Collapse
Affiliation(s)
- Stephen Booth
- Oxford NIHR Biomedical Research CentreDepartment of HaematologyChurchill HospitalOxfordUK
| | - Helen M. Curley
- Institute of Cancer and Genomic SciencesUniversity of BirminghamBirminghamUK
| | - Csilla Varnai
- Institute of Cancer and Genomic SciencesUniversity of BirminghamBirminghamUK
- Centre for Computational BiologyUniversity of BirminghamBirminghamUK
| | - Roland Arnold
- Institute of Cancer and Genomic SciencesUniversity of BirminghamBirminghamUK
| | - Lennard Y. W. Lee
- Institute of Cancer and Genomic SciencesUniversity of BirminghamBirminghamUK
- Department of OncologyOxford UniversityOxfordUK
| | - Naomi A. Campton
- Institute of Translational MedicineBirmingham Health PartnersBirminghamUK
| | - Gordon Cook
- NIHR (Leeds) MIC, LeedsSt James's Teaching Hospital, University of LeedsLeedsUK
| | - Karin Purshouse
- Edinburgh Cancer Research CentreUniversity of EdinburghEdinburghUK
| | | | | | | | | | | | | | | | - David Wrench
- Guys and St Thomas' NHS Foundation TrustLondonUK
| | | | | | - Ruth Pettengell
- St Georges University Hospitals NHS Foundation TrustLondonUK
| | - Abigail Gault
- NCCC Northern Centre for Cancer CareThe Newcastle Upon Tyne NHS Foundation TrustNewcastleUK
| | - Sam Moody
- NCCC Northern Centre for Cancer CareThe Newcastle Upon Tyne NHS Foundation TrustNewcastleUK
| | | | | | | | - Jack Illingworth
- BarkingHavering and Redbridge University Hospitals NHS TrustEssexUK
| | | | | | - John Ashcroft
- NIHR (Leeds) MIC, LeedsSt James's Teaching Hospital, University of LeedsLeedsUK
- Mid Yorkshire Hospitals NHS TrustWakefieldUK
| | - Neil Rabin
- University College London HospitalsLondonUK
| | - Jonathan Carmichael
- NIHR (Leeds) MIC, LeedsSt James's Teaching Hospital, University of LeedsLeedsUK
| | - Jean‐Baptiste Cazier
- Institute of Cancer and Genomic SciencesUniversity of BirminghamBirminghamUK
- Centre for Computational BiologyUniversity of BirminghamBirminghamUK
| | - Rachel Kerr
- Department of OncologyOxford UniversityOxfordUK
| | - Gary Middleton
- Institute of Immunology and ImmunotherapyUniversity of BirminghamEdgbastonBirminghamUK
| | - Graham P. Collins
- Oxford NIHR Biomedical Research CentreDepartment of HaematologyChurchill HospitalOxfordUK
| | - Claire Palles
- Institute of Cancer and Genomic SciencesUniversity of BirminghamBirminghamUK
| | | |
Collapse
|
9
|
Várnai C, Palles C, Arnold R, Curley HM, Purshouse K, Cheng VWT, Booth S, Campton NA, Collins GP, Hughes DJ, Kulasekararaj AG, Lee AJX, Olsson-Brown AC, Sharma-Oates A, Van Hemelrijck M, Lee LYW, Kerr R, Middleton G, Cazier JB. Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19. JAMA Netw Open 2022; 5:e220130. [PMID: 35188551 PMCID: PMC8861846 DOI: 10.1001/jamanetworkopen.2022.0130] [Citation(s) in RCA: 30] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Accepted: 12/14/2021] [Indexed: 12/20/2022] Open
Abstract
Importance Large cohorts of patients with active cancers and COVID-19 infection are needed to provide evidence of the association of recent cancer treatment and cancer type with COVID-19 mortality. Objective To evaluate whether systemic anticancer treatments (SACTs), tumor subtypes, patient demographic characteristics (age and sex), and comorbidities are associated with COVID-19 mortality. Design, Setting, and Participants The UK Coronavirus Cancer Monitoring Project (UKCCMP) is a prospective cohort study conducted at 69 UK cancer hospitals among adult patients (≥18 years) with an active cancer and a clinical diagnosis of COVID-19. Patients registered from March 18 to August 1, 2020, were included in this analysis. Exposures SACT, tumor subtype, patient demographic characteristics (eg, age, sex, body mass index, race and ethnicity, smoking history), and comorbidities were investigated. Main Outcomes and Measures The primary end point was all-cause mortality within the primary hospitalization. Results Overall, 2515 of 2786 patients registered during the study period were included; 1464 (58%) were men; and the median (IQR) age was 72 (62-80) years. The mortality rate was 38% (966 patients). The data suggest an association between higher mortality in patients with hematological malignant neoplasms irrespective of recent SACT, particularly in those with acute leukemias or myelodysplastic syndrome (OR, 2.16; 95% CI, 1.30-3.60) and myeloma or plasmacytoma (OR, 1.53; 95% CI, 1.04-2.26). Lung cancer was also significantly associated with higher COVID-19-related mortality (OR, 1.58; 95% CI, 1.11-2.25). No association between higher mortality and receiving chemotherapy in the 4 weeks before COVID-19 diagnosis was observed after correcting for the crucial confounders of age, sex, and comorbidities. An association between lower mortality and receiving immunotherapy in the 4 weeks before COVID-19 diagnosis was observed (immunotherapy vs no cancer therapy: OR, 0.52; 95% CI, 0.31-0.86). Conclusions and Relevance The findings of this study of patients with active cancer suggest that recent SACT is not associated with inferior outcomes from COVID-19 infection. This has relevance for the care of patients with cancer requiring treatment, particularly in countries experiencing an increase in COVID-19 case numbers. Important differences in outcomes among patients with hematological and lung cancers were observed.
Collapse
Affiliation(s)
- Csilla Várnai
- Centre for Computational Biology, University of Birmingham, Birmingham, United Kingdom
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom
- Cancer Research UK Birmingham Centre, University of Birmingham, United Kingdom
| | - Claire Palles
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom
| | - Roland Arnold
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom
| | - Helen M. Curley
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom
| | - Karin Purshouse
- Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, United Kingdom
| | - Vinton W. T. Cheng
- Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom
| | - Stephen Booth
- Oxford NIHR Biomedical Research Centre, Department of Haematology, Churchill Hospital, Oxford, United Kingdom
| | - Naomi A. Campton
- Institute of Translational Medicine, Birmingham Health Partners, Birmingham, United Kingdom
| | - Graham P. Collins
- Oxford NIHR Biomedical Research Centre, Department of Haematology, Churchill Hospital, Oxford, United Kingdom
| | - Daniel J. Hughes
- Department of Cancer Imaging, King’s College London, London, United Kingdom
| | | | - Alvin J. X. Lee
- UCL Cancer Institute, University College London, London, United Kingdom
| | - Anna C. Olsson-Brown
- The Clatterbridge Cancer Centre, Wirral, United Kingdom
- The University of Liverpool, Liverpool, United Kingdom
| | - Archana Sharma-Oates
- Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom
| | - Mieke Van Hemelrijck
- Translational Oncology and Urology Research, School of Cancer and Pharmaceutical Sciences, King’s College London, London, United Kingdom
| | - Lennard Y. W. Lee
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom
- Department of Oncology, Oxford University, Oxford, United Kingdom
| | - Rachel Kerr
- Department of Oncology, Oxford University, Oxford, United Kingdom
| | - Gary Middleton
- Cancer Research UK Birmingham Centre, University of Birmingham, United Kingdom
- Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham, United Kingdom
- Queen Elizabeth Hospital, Birmingham, United Kingdom
| | - Jean-Baptiste Cazier
- Centre for Computational Biology, University of Birmingham, Birmingham, United Kingdom
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom
- Cancer Research UK Birmingham Centre, University of Birmingham, United Kingdom
- Queen Elizabeth Hospital, Birmingham, United Kingdom
| |
Collapse
|
10
|
Albargi H, Mallett S, Berhane S, Booth S, Hawkes C, Perkins GD, Norton M, Foster T, Scholefield B. Bystander cardiopulmonary resuscitation for paediatric out-of-hospital cardiac arrest in England: An observational registry cohort study. Resuscitation 2021; 170:17-25. [PMID: 34748765 DOI: 10.1016/j.resuscitation.2021.10.042] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2021] [Revised: 10/23/2021] [Accepted: 10/28/2021] [Indexed: 01/14/2023]
Abstract
INTRODUCTION Bystander cardiopulmonary resuscitation (BCPR) is strongly advocated by resuscitation councils for paediatric out-of-hospital cardiac arrests (OHCAs). However, there are limited reports on rates of BCPR in children and its relationship with return of spontaneous circulation (ROSC) or survival outcomes. OBJECTIVE We describe the rate of BCPR and its association with any ROSC and survival- to- hospital-discharge. METHODS We conducted retrospective analysis of prospectively collected paediatric (<18 years of age) OHCA cases in England; we included specialist registry patients treated by emergency medical services (EMS) with known BCPR status and outcome between January 2014 and November 2018. Data included patient demographics, aetiology, witness status, initial rhythm, EMS, season, time of day and bystander status. Associations between BCPR, and any ROSC and survival-to-hospital-discharge outcomes were explored using multivariable logistic regression. RESULTS There were 2363 paediatric OHCAs treated across 11 EMS regions. BCPR was performed in 69.6% (1646/2363) of the cases overall (range 57.7% (206/367) to 83.7% (139/166) across EMS regions). Only 34.9% (550/1572) of BCPR cases were witnessed. Overall, any ROSC was achieved in 22.8% (523/2289) and survival to hospital discharge in 10.8% (225/2066). Adjusted odds ratio (aOR) for any ROSC was significantly improved following BCPR compared to no BCPR (aOR 1.37, 95% CI 1.03-1.81), but adjusted odds ratio for survival-to-hospital-discharge were similar (aOR 1.01, 95% CI 0.66-1.55). CONCLUSIONS BCPR was associated with improved rates of any ROSC but not survival-to-hospital-discharge. Variations in EMS BCPR rates may indicate opportunities for regional targeted increase in public BCPR education.
Collapse
Affiliation(s)
- H Albargi
- Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2TT, UK; Emergency Medical Services Department, Faculty of Applied Medical Science, Jazan University, Jazan, Saudi Arabia
| | - S Mallett
- UCL Centre for Medical, University College London, London W1W 7TY, UK
| | - S Berhane
- NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, UK; Institute of Applied Health Research, University of Birmingham, UK
| | - S Booth
- Clinical Trials Unit, University of Warwick Medical School, Coventry, UK
| | - C Hawkes
- Clinical Trials Unit, University of Warwick Medical School, Coventry, UK
| | - G D Perkins
- Clinical Trials Unit, University of Warwick Medical School, Coventry, UK; Department of Critical Care Medicine, Heartlands Hospital, University Hospitals Birmingham, B9 5SS, UK
| | - M Norton
- North East Ambulance Service NHS Foundation Trust, Bernicia House, Newburn Riverside, Newcastle upon Tyne NE15 8NY, UK; School of Medicine, University of Sunderland, Chester Road, Sunderland SR1 3SD, UK
| | - T Foster
- East of England Ambulance Service NHS Trust, Whiting Way, Melbourn, Cambs SG8 6EN, UK
| | - B Scholefield
- Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2TT, UK; Paediatric Intensive Care Unit, Birmingham Women's and Children's NHS Foundation Trust, Birmingham B4 6NH, UK.
| |
Collapse
|
11
|
Kazmi F, Shrestha N, Booth S, Dodwell D, Aroldi F, Foord T, Nicholson BD, Heesen P, Lord S, Yeoh KW, Blagden S. Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer. Hippokratia 2021. [DOI: 10.1002/14651858.cd014872] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Farasat Kazmi
- Department of Oncology; University of Oxford; Oxford UK
| | - Nipun Shrestha
- Department of Primary Care and Mental Health; University of Liverpool; Liverpool UK
| | - Stephen Booth
- Department of Oncology; University of Oxford; Oxford UK
| | - David Dodwell
- Nuffield Department of Population Health; University of Oxford; Oxford UK
| | | | | | - Brian D Nicholson
- Nuffield Department of Primary Care Health Sciences; University of Oxford; Oxford UK
| | | | - Simon Lord
- Department of Oncology; University of Oxford; Oxford UK
| | - Kheng-Wei Yeoh
- Radiation Oncology; National Cancer Centre; Singapore Singapore
| | - Sarah Blagden
- Department of Oncology; University of Oxford; Oxford UK
| |
Collapse
|
12
|
Naylor S, Booth S, Harvey-Lloyd J, Strudwick R. Experiences of diagnostic radiographers through the Covid-19 pandemic. Radiography (Lond) 2021; 28:187-192. [PMID: 34736824 PMCID: PMC8552557 DOI: 10.1016/j.radi.2021.10.016] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2021] [Revised: 10/19/2021] [Accepted: 10/20/2021] [Indexed: 12/23/2022]
Abstract
Introduction Diagnostic Radiography plays a major role in the diagnosis and management of patients with Covid-19. This has seen an increase in the demand for imaging services, putting pressure on the workforce. Diagnostic radiographers, as with many other healthcare professions, have been on the frontline, dealing with an unprecedented situation. This research aimed to explore the experience of diagnostic radiographers working clinically during the Covid-19 pandemic. Methods Influenced by interpretative phenomenology, this study explored the experiences of diagnostic radiographers using virtual focus group interviews as a method of data collection. Results Data were analysed independently by four researchers and five themes emerged from the data. Adapting to new ways of working, feelings and emotions, support mechanisms, self-protection and resilience, and professional recognition. Conclusion The adaptability of radiographers came across strongly in this study. Anxieties attributed to the provision of personal protective equipment (PPE), fear of contracting the virus and spreading it to family members were evident. The resilience of radiographers working throughout this pandemic came across strongly throughout this study. A significant factor for coping has been peer support from colleagues within the workplace. The study highlighted the lack of understanding of the role of the radiographer and how the profession is perceived by other health care professionals. Implications for practice This study highlights the importance of interprofessional working and that further work is required in the promotion of the profession.
Collapse
Affiliation(s)
- S Naylor
- University of Derby, Kedleston Rd, Derby DE22 1GB, UK.
| | - S Booth
- University of Salford, Allerton Building, University of Salford, Manchester M6 6PU, UK.
| | - J Harvey-Lloyd
- University of Suffolk, Waterfront Building, 19 Neptune Quay, Ipswich IP4 1QJ, UK.
| | - R Strudwick
- University of Suffolk, Waterfront Building, 19 Neptune Quay, Ipswich IP4 1QJ, UK.
| |
Collapse
|
13
|
Pagano L, Salmanton-García J, Marchesi F, Busca A, Corradini P, Hoenigl M, Klimko N, Koehler P, Pagliuca A, Passamonti F, Verga L, Víšek B, Ilhan O, Nadali G, Weinbergerová B, Córdoba-Mascuñano R, Marchetti M, Collins GP, Farina F, Cattaneo C, Cabirta A, Gomes-Silva M, Itri F, van Doesum J, Ledoux MP, Čerňan M, Jakšić O, Duarte RF, Magliano G, Omrani AS, Fracchiolla NS, Kulasekararaj A, Valković T, Poulsen CB, Machado M, Glenthøj A, Stoma I, Ráčil Z, Piukovics K, Navrátil M, Emarah Z, Sili U, Maertens J, Blennow O, Bergantim R, García-Vidal C, Prezioso L, Guidetti A, del Principe MI, Popova M, de Jonge N, Ormazabal-Vélez I, Fernández N, Falces-Romero I, Cuccaro A, Meers S, Buquicchio C, Antić D, Al-Khabori M, García-Sanz R, Biernat MM, Tisi MC, Sal E, Rahimli L, Čolović N, Schönlein M, Calbacho M, Tascini C, Miranda-Castillo C, Khanna N, Méndez GA, Petzer V, Novák J, Besson C, Duléry R, Lamure S, Nucci M, Zambrotta G, Žák P, Seval GC, Bonuomo V, Mayer J, López-García A, Sacchi MV, Booth S, Ciceri F, Oberti M, Salvini M, Izuzquiza M, Nunes-Rodrigues R, Ammatuna E, Obr A, Herbrecht R, Núñez-Martín-Buitrago L, Mancini V, Shwaylia H, Sciumè M, Essame J, Nygaard M, Batinić J, Gonzaga Y, Regalado-Artamendi I, Karlsson LK, Shapetska M, Hanakova M, El-Ashwah S, Borbényi Z, Çolak GM, Nordlander A, Dragonetti G, Maraglino AME, Rinaldi A, De Ramón-Sánchez C, Cornely OA. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol 2021; 14:168. [PMID: 34649563 PMCID: PMC8515781 DOI: 10.1186/s13045-021-01177-0] [Citation(s) in RCA: 156] [Impact Index Per Article: 52.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2021] [Accepted: 09/25/2021] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality. METHODS The survey was supported by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confirmed COVID-19 observed between March and December 2020. RESULTS The study sample includes 3801 cases, represented by lymphoproliferative (mainly non-Hodgkin lymphoma n = 1084, myeloma n = 684 and chronic lymphoid leukemia n = 474) and myeloproliferative malignancies (mainly acute myeloid leukemia n = 497 and myelodysplastic syndromes n = 279). Severe/critical COVID-19 was observed in 63.8% of patients (n = 2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID-19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate significantly decreased between the first COVID-19 wave (March-May 2020) and the second wave (October-December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value < 0.0001). In the multivariable analysis, age, active malignancy, chronic cardiac disease, liver disease, renal impairment, smoking history, and ICU stay correlated with mortality. Acute myeloid leukemia was a higher mortality risk than lymphoproliferative diseases. CONCLUSIONS This survey confirms that COVID-19 patients with HM are at high risk of lethal complications. However, improved COVID-19 prevention has reduced mortality despite an increase in the number of reported cases.
Collapse
Affiliation(s)
- Livio Pagano
- Hematology, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS – Università Cattolica del Sacro Cuore, Rome, Italy
- Università Cattolica del Sacro Cuore, Rome, Italy
| | - Jon Salmanton-García
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Excellence Center for Medical Mycology (ECMM), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
- Cologne Excellence Cluster On Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
| | - Francesco Marchesi
- Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy
| | - Alessandro Busca
- Stem Cell Transplant Center, AOU Citta’ Della Salute E Della Scienza, Turin, Italy
| | - Paolo Corradini
- University of Milan and Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
| | - Martin Hoenigl
- Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, CA USA
- Clinical and Translational Fungal-Working Group, University of California San Diego, La Jolla, CA USA
- Section of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Medical University of Graz, Graz, Austria
| | - Nikolai Klimko
- North-Western State Medical University Named After Iliá Ilich Méchnikov, Saint-Petersburg, Russia
| | - Philipp Koehler
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Excellence Center for Medical Mycology (ECMM), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
- Cologne Excellence Cluster On Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
| | - Antonio Pagliuca
- Department of Hematological Medicine, King’s College Hospital NHS Foundation Trust, London, UK
| | - Francesco Passamonti
- Department of Medicine and Surgery, University of Insubria, ASST Sette Laghi, Ospedale Di Circolo of Varese, Varese, Italy
| | - Luisa Verga
- Azienda Ospedaliera San Gerardo - Monza, Monza, Italy
- Università Milano-Bicocca, Milan, Italy
| | - Benjamin Víšek
- University Hospital Hradec Králové, Hradec Králové, Czech Republic
| | | | | | - Barbora Weinbergerová
- Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic
| | - Raúl Córdoba-Mascuñano
- Fundacion Jimenez Díaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain
| | - Monia Marchetti
- Hematology and BMT Unit, Azienda Ospedaliera Nazionale SS. Antonio E Biagio E Cesare Arrigo, Alessandria, Italy
| | - Graham P. Collins
- NIHR Oxford Biomedical Research Centre, Churchill Hospital, Oxford, UK
| | - Francesca Farina
- Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | | | - Alba Cabirta
- Department of Hematology, Vall d’Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
- Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain
| | | | - Federico Itri
- San Luigi Gonzaga Hospital - Orbassano, Orbassano, Italy
| | | | | | - Martin Čerňan
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
| | - Ozren Jakšić
- Department of Hematology, University Hospital Dubrava, Zagreb, Croatia
| | | | | | - Ali S. Omrani
- Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar
| | | | | | - Toni Valković
- University Hospital Centre Rijeka, Rijeka, Croatia
- Croatian Cooperative Group for Hematological Diseases (CROHEM), Zagreb, Croatia
- Faculty of Medicine and Faculty of Health Studies, University of Rijeka, Rijeka, Croatia
| | | | - Marina Machado
- Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | | | - Igor Stoma
- Gomel State Medical University, Gomel, Belarus
| | - Zdeněk Ráčil
- Institute of Hematology and Blood Transfusion, Prague, Czech Republic
| | - Klára Piukovics
- Department of Internal Medicine, Albert Szent-Györgyi Health Center, Faculty of Medicine, University of Szeged, Szeged, Hungary
| | | | - Ziad Emarah
- Oncology Center, Mansoura University, Mansoura, Egypt
| | | | | | - Ola Blennow
- Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
| | - Rui Bergantim
- 3S-Instituto de Investigação E Inovação Em Saúde, Universidade Do Porto, Porto, Portugal
- Cancer Drug Resistance Group, IPATIMUP-Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal
- Clinical Hematology, Centro Hospitalar E Universitário São João, Porto, Portugal
- Clinical Hematology, Faculty of Medicine, University of Porto, Porto, Portugal
| | | | - Lucia Prezioso
- U.O. Ematologia E Centro Trapianti Midollo Osseo, Ospedale Maggiore, Parma, Italy
| | - Anna Guidetti
- Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy
| | | | - Marina Popova
- Hematology and Transplantation, Raisa Gorbacheva Research Institute of Pediatric Oncology, Pavlov University, St. Petersburg, Russia
| | - Nick de Jonge
- Amsterdam UMC, Location VUmc, Amsterdam, Netherlands
| | | | - Noemí Fernández
- Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | | | - Annarosa Cuccaro
- Hematology Unit, Center for Translational Medicine, Azienda USL Toscana NordOvest, Livorno, Italy
| | | | | | - Darko Antić
- Clinic of Hematology, University Clinical Center of Serbia, Belgrade, Serbia
- Faculty of Medicine, University of Belgrade, Belgrade, Serbia
| | | | - Ramón García-Sanz
- Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain
- IBSAL, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain
| | - Monika M. Biernat
- Department of Haematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University, Wrocław, Poland
| | | | - Ertan Sal
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Excellence Center for Medical Mycology (ECMM), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
- Cologne Excellence Cluster On Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
| | - Laman Rahimli
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Excellence Center for Medical Mycology (ECMM), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
- Cologne Excellence Cluster On Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
| | - Natasa Čolović
- Clinic of Hematology, University Clinical Center of Serbia, Belgrade, Serbia
- Faculty of Medicine, University of Belgrade, Belgrade, Serbia
| | - Martin Schönlein
- Department of Oncology, Hematology and Bone Marrow Transplantation With Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | | | - Carlo Tascini
- Azienda Sanitaria Universitaria del Friuli Centrale, Udine, Italy
| | | | - Nina Khanna
- Division of Infectious Diseases and Hospital Epidemiology, Department of Clinical Research, University and University Hospital of Basel, Basel, Switzerland
| | | | - Verena Petzer
- Department of Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria
| | - Jan Novák
- University Hospital of Královské Vinohrady, Prague, Czech Republic
| | | | - Rémy Duléry
- Service d’Hématologie Clinique Et de Thérapie Cellulaire, Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Inserm UMRs 938, Paris, France
| | - Sylvain Lamure
- Departement d’Hematologie Clinique, CHU de Montpellier, UMR-CNRS 5535, Universite de Montpellier, Montpellier, France
| | - Marcio Nucci
- Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
| | - Giovanni Zambrotta
- Azienda Ospedaliera San Gerardo - Monza, Monza, Italy
- Università Milano-Bicocca, Milan, Italy
| | - Pavel Žák
- University Hospital Hradec Králové, Hradec Králové, Czech Republic
| | | | | | - Jiří Mayer
- Department of Internal Medicine, Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic
| | - Alberto López-García
- Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain
| | - Maria Vittoria Sacchi
- Hematology and BMT Unit, Azienda Ospedaliera Nazionale SS. Antonio E Biagio E Cesare Arrigo, Alessandria, Italy
| | - Stephen Booth
- NIHR Oxford Biomedical Research Centre, Churchill Hospital, Oxford, UK
| | - Fabio Ciceri
- Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | | | - Marco Salvini
- Department of Medicine and Surgery, University of Insubria, ASST Sette Laghi, Ospedale Di Circolo of Varese, Varese, Italy
| | - Macarena Izuzquiza
- Department of Hematology, Vall d’Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
- Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain
| | | | | | - Aleš Obr
- Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
| | | | | | | | - Hawraa Shwaylia
- National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar
| | - Mariarita Sciumè
- Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
| | | | | | - Josip Batinić
- Croatian Cooperative Group for Hematological Diseases (CROHEM), Zagreb, Croatia
- University Hospital Centre Zagreb, Zagreb, Croatia
- Faculty of Medicine, University of Zagreb, Zagreb, Croatia
| | - Yung Gonzaga
- Hematology Service, Instituto Nacional Do Cancer, Rio de Janeiro, Brazil
| | - Isabel Regalado-Artamendi
- Haematology and Haemotherapy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | | | - Maryia Shapetska
- Scientific and Practical Center for Surgery, Transplantology and Hematology, Minsk, Belarus
| | - Michaela Hanakova
- Institute of Hematology and Blood Transfusion, Prague, Czech Republic
| | | | - Zita Borbényi
- Department of Internal Medicine, Albert Szent-Györgyi Health Center, Faculty of Medicine, University of Szeged, Szeged, Hungary
| | | | - Anna Nordlander
- Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
- Department of Cell Therapy and Allogenic Stem Cell Transplantation (CAST), Karolinska University Hospital, Stockholm, Sweden
| | - Giulia Dragonetti
- Hematology, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS – Università Cattolica del Sacro Cuore, Rome, Italy
- Università Cattolica del Sacro Cuore, Rome, Italy
| | - Alessio Maria Edoardo Maraglino
- Hematology, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS – Università Cattolica del Sacro Cuore, Rome, Italy
- Università Cattolica del Sacro Cuore, Rome, Italy
| | - Amelia Rinaldi
- U.O. Ematologia E Centro Trapianti Midollo Osseo, Ospedale Maggiore, Parma, Italy
| | - Cristina De Ramón-Sánchez
- Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Hospital Universitario de Salamanca, IBSAL, Salamanca, Spain
| | - Oliver A. Cornely
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Excellence Center for Medical Mycology (ECMM), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
- Chair Translational Research, Cologne Excellence Cluster On Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
- Clinical Trials Centre Cologne (ZKS Köln), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
- Center for Molecular Medicine Cologne (CMMC), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
- German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany
| |
Collapse
|
14
|
Booth S, Danek A, Farris A, Nunnery D, Griffin J. Implementing a Video Intervention to Improve Food Security and Promote Weight Loss in a Rural, Low-Income Population. J Acad Nutr Diet 2021. [DOI: 10.1016/j.jand.2021.06.254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
15
|
Booth S, Kirkwood A, Johnson P, Barrington S, Gallop‐Evans E, Peggs K, Warbey V, Burton C, Ardavan A, Phillips B, Lawrie E, Pike L, Northend M, Clifton‐Hadley L, Jenner R, Collins GP. ANIMATE: A PHASE II STUDY OF NIVOLUMAB IN TRANSPLANT ELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.159_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- S. Booth
- Oxford University Hospitals Department of Haematology Oxford UK
| | - A. Kirkwood
- UCL Cancer Institute CR UK and UCL Cancer Trials Centre London UK
| | - P. Johnson
- University of Southampton Department of Medicine London UK
| | - S. Barrington
- King’s College London King’s College London and Guys’ & St Thomas PET Imaging Centre London UK
| | - E. Gallop‐Evans
- Velindre University NHS Trust Department of Oncology Cardiff UK
| | - K. Peggs
- University College London Hospitals Haematology London UK
| | - V. Warbey
- King’s College London King’s College London and Guys’ & St Thomas PET Imaging Centre London UK
| | - C. Burton
- Leeds Cancer Centre Haematology Leeds UK
| | - A. Ardavan
- University of Oxford Department of Physics Oxford UK
| | - B. Phillips
- University of Manchester and Manchester Academic Health Science Centre Division of Cancer Science Manchester UK
| | - E. Lawrie
- UCL Cancer Institute CR UK and UCL Cancer Trials Centre London UK
| | - L. Pike
- King’s College London King’s College London and Guys’ & St Thomas PET Imaging Centre London UK
| | - M. Northend
- UCL Cancer Institute CR UK and UCL Cancer Trials Centre London UK
| | | | - R. Jenner
- UCL Cancer Institute CR UK and UCL Cancer Trials Centre London UK
| | - G. P. Collins
- Oxford University Hospitals Department of Haematology Oxford UK
| |
Collapse
|
16
|
Santarsieri A, Sturgess K, Brice P, Menne TF, Osborne W, Creasey T, Ardeshna KM, Behan S, Bhuller K, Booth S, Collins GP, Cwynarski K, Furtado M, Iyenga S, Jones SG, O'Mahony D, Martinez‐Calle N, McKay P, Nagumantry SK, Rudge JF, Shah N, Stafford G, Sternberg A, Uttenthal BJ, McMillan AK, Follows GA. MODIFICATION OF ESCALATED BEACOPP WITH DACARBAZINE SUBSTITUTION REDUCES TOXICITY WHILE MAINTAINING EFFICACY FOR THE TREATMENT OF ADVANCED STAGE HODGKIN LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.109_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- A. Santarsieri
- Cambridge University Hospitals NHS Foundation Trust Haematology Cambridge UK
| | - K. Sturgess
- Cambridge University Hospitals NHS Foundation Trust Haematology Cambridge UK
| | - P. Brice
- Hôpital Saint‐Louis Hématologie‐Oncologie Paris France
| | - T. F. Menne
- Freeman Hospital Newcastle Upon Tyne Hospitals NHS Foundation Trust Haematology Newcastle UK
| | - W. Osborne
- Freeman Hospital Newcastle Upon Tyne Hospitals NHS Foundation Trust Haematology Newcastle UK
| | - T. Creasey
- Newcastle University Hospitals NHSFT Haematology Newcastle UK
| | - K. M. Ardeshna
- University College London Hospitals NHS Foundation Trust Haematology London UK
| | - S. Behan
- Cambridge University Hospitals NHS Foundation Trust Haematology Cambridge UK
| | - K. Bhuller
- University Hospitals of Leicester NHS Trust Haematology Leicester UK
| | - S. Booth
- Oxford University Hospitals NHS Foundation Trust Haematology Oxford UK
| | - G. P. Collins
- Oxford University Hospitals NHS Foundation Trust Haematology Oxford UK
| | - K. Cwynarski
- University College London Hospitals NHS Foundation Trust Haematology London UK
| | - M. Furtado
- Royal Cornwall Hospitals NHS Trust Haematology Cornwall UK
| | - S. Iyenga
- The Royal Marsden NHS Foundation Trust Haematology London UK
| | - S. G. Jones
- Sherwood Forest Hospitals NHS Foundation Trust Haematology Nottinghamshire UK
| | - D. O'Mahony
- Cork University Hospital Oncology Cork Ireland
| | | | - P. McKay
- Beatson West of Scotland Cancer Centre Haematology Glasgow UK
| | - S. K. Nagumantry
- Peterborough City Hospital North West Anglia NHS Foundation Trust Haematology Peterborough UK
| | - J. F. Rudge
- Bullard Laboratories University of Cambridge Cambridge UK
| | - N. Shah
- Norfolk and Norwich University Hospitals NHS Foundation Trust Haematology Cambridge UK
| | - G. Stafford
- Cambridge University Hospitals NHS Foundation Trust Haematology Cambridge UK
| | - A. Sternberg
- Great Western Hospitals NHS Foundation Trust Haematology Swindon UK
| | - B. J. Uttenthal
- Cambridge University Hospitals NHS Foundation Trust Haematology Cambridge UK
| | - A. K. McMillan
- Nottingham University Hospitals NHS Trust Haematology Nottingham UK
| | - G. A. Follows
- Cambridge University Hospitals NHS Foundation Trust Haematology Cambridge UK
| |
Collapse
|
17
|
Collins GP, Booth S, Cherrill LR, Slade D, Morland C, Hopkins L, Nagy E, Linton K, Fox CP, Lewis D, Davies A, Turner G, Rees G, Yap C, Cwynarski K. ROMIDEPSIN AND CARFILZOMIB IN RELAPSED / REFRACTORY PERIPHERAL T‐CELL LYMPHOMA WITH ASSESSMENT OF H23B AS A PREDICTIVE BIOMARKER – THE UK NCRI SEAMLESS PHASE 1/2 ROMICAR TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.126_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- G. P. Collins
- NIHR Oxford Biomedical Research Centre Churchill Hospital Haematology Oxford UK
| | - S. Booth
- Churchill Hospital Clinical Haematology Oxford UK
| | - L. R. Cherrill
- Birmingham University Cancer Research UK Clinical Trials Unit Birmingham UK
| | - D. Slade
- Birmingham University Cancer Research UK Clinical Trials Unit Birmingham UK
| | - C. Morland
- Birmingham University Cancer Research UK Clinical Trials Unit Birmingham UK
| | - L. Hopkins
- Birmingham University Cancer Research UK Clinical Trials Unit Birmingham UK
| | - E. Nagy
- Birmingham University Cancer Research UK Clinical Trials Unit Birmingham UK
| | - K. Linton
- Christie Hospital Medical onology Manchester UK
| | - C. P. Fox
- Nottingham University Hospitals NHS Foundation Trust Haematology Nottingham UK
| | - D. Lewis
- Plymouth Hospitals NHS Trust Haematology Plymouth UK
| | - A. Davies
- University of Southampton CRUK/NIHR Experimental Cancer Medicines Centre Southampton UK
| | - G. Turner
- Oxford University Hospitals NHS Foundation Trust Cellular Pathology Oxford UK
| | - G. Rees
- Oxford University Hospitals NHS Foundation Trust Cellular Pathology Oxford UK
| | - C. Yap
- Institute of Cancer Research Clinical Studies London UK
| | - K. Cwynarski
- University College London Hospitals NHS Foundation Trust Haematology London UK
| |
Collapse
|
18
|
Young AE, Thet NT, Mercer-Chalmers J, Greenwood RJ, Coy K, Booth S, Sack A, Jenkins ATA. The SPaCE diagnostic: a pilot study to test the accuracy of a novel point of care sensor for point of care detection of burn wound infection. J Hosp Infect 2020; 106:726-733. [PMID: 33022335 DOI: 10.1016/j.jhin.2020.09.033] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2020] [Revised: 09/28/2020] [Accepted: 09/28/2020] [Indexed: 10/23/2022]
Abstract
BACKGROUND Wound infection in burn patients is common and has an impact on outcomes. There is no objective method to diagnose infection at point of care (PoC). Early diagnosis prevents progression to sepsis. Diagnostic subjectivity supports over-diagnosis, unnecessary hospitalization, and antibiotic overuse. AIM This pilot study aimed to investigate the accuracy of a novel PoC wound infection diagnostic in burn patients. METHODS We produced, and in vitro tested, a PoC diagnostic for early wound infection diagnosis. The prototype SPaCE diagnostic uses a patented lipid vesicle suspension into which a clinical swab is placed. The diagnostic delivers a colour-response to Staphylococcus aureus, Pseudomonas aeruginosa, Candida species and Enterococcus faecalis at toxin release. A pilot clinical diagnostic accuracy study was undertaken. The reference standard was a retrospective decision made by an expert clinical panel using routinely available data. FINDINGS Data was available from 33 of 34 patients. Of these, 52% were considered to have a wound infection, 42% not, and two (6%) were equivocal. The diagnostic results showed 24% were infected, 42% were not and 33% produced intermediate results. Agreement between clinical judgement and diagnostic result, assessed using a weighted Kappa, was 0.591 suggesting moderate agreement. If the intermediate results were excluded, 22 sets of data with definitive results achieved a Kappa statistic of 0.81 suggesting 'almost perfect' agreement. Sensitivity and specificity were 57% (8/14) and 71% (12/17), respectively. CONCLUSION This pilot study provided evidence that the SPaCE diagnostic could provide valuable and timely data to support clinical decision-making at PoC for wound infection.
Collapse
Affiliation(s)
- A E Young
- Children's Burn Research Centre, University Hospital Bristol and Weston NHS Foundation Trust, Bristol, UK; Bristol Centre for Surgical Research, Bristol Medical School University of Bristol, Bristol, UK.
| | - N T Thet
- Chemistry Department, University of Bath, Bath, UK
| | | | - R J Greenwood
- Research Design Service, Education Centre, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK
| | - K Coy
- Bristol Centre for Surgical Research, Bristol Medical School University of Bristol, Bristol, UK
| | - S Booth
- Queen Victoria Hospital NHS Foundation Trust, East Grinstead, UK
| | - A Sack
- Southmead Hospital, North Bristol NHS Foundation Trust, Bristol, UK
| | | |
Collapse
|
19
|
Davies A, Teare L, Falder S, Dumville J, Shah M, Jenkins A, Collins D, Dheansa B, Coy K, Booth S, Moore L, Marlow K, Agha R, Young A. Consensus demonstrates four indicators needed to standardize burn wound infection reporting across trials in a single-country study (ICon-B study). J Hosp Infect 2020; 106:217-225. [DOI: 10.1016/j.jhin.2020.07.022] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2020] [Accepted: 07/22/2020] [Indexed: 01/10/2023]
|
20
|
Lee LYW, Cazier JB, Starkey T, Briggs SEW, Arnold R, Bisht V, Booth S, Campton NA, Cheng VWT, Collins G, Curley HM, Earwaker P, Fittall MW, Gennatas S, Goel A, Hartley S, Hughes DJ, Kerr D, Lee AJX, Lee RJ, Lee SM, Mckenzie H, Middleton CP, Murugaesu N, Newsom-Davis T, Olsson-Brown AC, Palles C, Powles T, Protheroe EA, Purshouse K, Sharma-Oates A, Sivakumar S, Smith AJ, Topping O, Turnbull CD, Várnai C, Briggs ADM, Middleton G, Kerr R. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol 2020; 21:1309-1316. [PMID: 32853557 PMCID: PMC7444972 DOI: 10.1016/s1470-2045(20)30442-3] [Citation(s) in RCA: 399] [Impact Index Per Article: 99.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2020] [Revised: 07/15/2020] [Accepted: 07/21/2020] [Indexed: 02/06/2023]
Abstract
BACKGROUND Patients with cancer are purported to have poor COVID-19 outcomes. However, cancer is a heterogeneous group of diseases, encompassing a spectrum of tumour subtypes. The aim of this study was to investigate COVID-19 risk according to tumour subtype and patient demographics in patients with cancer in the UK. METHODS We compared adult patients with cancer enrolled in the UK Coronavirus Cancer Monitoring Project (UKCCMP) cohort between March 18 and May 8, 2020, with a parallel non-COVID-19 UK cancer control population from the UK Office for National Statistics (2017 data). The primary outcome of the study was the effect of primary tumour subtype, age, and sex and on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prevalence and the case-fatality rate during hospital admission. We analysed the effect of tumour subtype and patient demographics (age and sex) on prevalence and mortality from COVID-19 using univariable and multivariable models. FINDINGS 319 (30·6%) of 1044 patients in the UKCCMP cohort died, 295 (92·5%) of whom had a cause of death recorded as due to COVID-19. The all-cause case-fatality rate in patients with cancer after SARS-CoV-2 infection was significantly associated with increasing age, rising from 0·10 in patients aged 40-49 years to 0·48 in those aged 80 years and older. Patients with haematological malignancies (leukaemia, lymphoma, and myeloma) had a more severe COVID-19 trajectory compared with patients with solid organ tumours (odds ratio [OR] 1·57, 95% CI 1·15-2·15; p<0·0043). Compared with the rest of the UKCCMP cohort, patients with leukaemia showed a significantly increased case-fatality rate (2·25, 1·13-4·57; p=0·023). After correction for age and sex, patients with haematological malignancies who had recent chemotherapy had an increased risk of death during COVID-19-associated hospital admission (OR 2·09, 95% CI 1·09-4·08; p=0·028). INTERPRETATION Patients with cancer with different tumour types have differing susceptibility to SARS-CoV-2 infection and COVID-19 phenotypes. We generated individualised risk tables for patients with cancer, considering age, sex, and tumour subtype. Our results could be useful to assist physicians in informed risk-benefit discussions to explain COVID-19 risk and enable an evidenced-based approach to national social isolation policies. FUNDING University of Birmingham and University of Oxford.
Collapse
Affiliation(s)
- Lennard Y W Lee
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK; Department of Oncology, University of Oxford, Oxford, UK; University Hospitals Birmingham, Birmingham, UK
| | - Jean-Baptiste Cazier
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK; Centre for Computational Biology, University of Birmingham, Birmingham, UK
| | - Thomas Starkey
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
| | - Sarah E W Briggs
- Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Roland Arnold
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
| | - Vartika Bisht
- Centre for Computational Biology, University of Birmingham, Birmingham, UK
| | - Stephen Booth
- Department of Haematology, University of Oxford, Oxford, UK
| | - Naomi A Campton
- Institute of Translational Medicine, Birmingham Health Partners, Birmingham, UK
| | - Vinton W T Cheng
- Leeds Institute of Medical Research, University of Leeds, Leeds, UK
| | - Graham Collins
- Department of Haematology, University of Oxford, Oxford, UK
| | - Helen M Curley
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
| | | | | | | | - Anshita Goel
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
| | - Simon Hartley
- Centre for Computational Biology, University of Birmingham, Birmingham, UK; Advanced Research Computing, University of Birmingham, Birmingham, UK
| | - Daniel J Hughes
- Department of Cancer Imaging, King's College London, London, UK
| | - David Kerr
- Nuffield Division of Clinical and Laboratory Services, University of Oxford, Oxford, UK
| | - Alvin J X Lee
- UCL Cancer Institute, University College London, London, UK
| | - Rebecca J Lee
- The University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK
| | | | | | - Chris P Middleton
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK; Centre for Computational Biology, University of Birmingham, Birmingham, UK
| | - Nirupa Murugaesu
- St George's University Hospitals NHS Foundation Trust, London, UK
| | - Tom Newsom-Davis
- Chelsea and Westminster Hospital NHS Foundation Trust, London, UK
| | | | - Claire Palles
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
| | | | - Emily A Protheroe
- University of Birmingham Medical School, University of Birmingham, Birmingham, UK
| | - Karin Purshouse
- Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK
| | | | | | | | | | - Chris D Turnbull
- Nuffield Department of Medicine, University of Oxford, Oxford, UK
| | - Csilla Várnai
- Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK; Centre for Computational Biology, University of Birmingham, Birmingham, UK
| | | | - Gary Middleton
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; University Hospitals Birmingham, Birmingham, UK.
| | - Rachel Kerr
- Department of Oncology, University of Oxford, Oxford, UK
| |
Collapse
|
21
|
Booth S, Willan J, Wong H, Khan D, Farnell R, Hunter A, Eyre T, Katz H, Dungarwalla M, Chen L, Browning J, Polzella P, Gray N, Neelakantan P, Dhillon EK, Dutton D, Sternberg A, Prideaux S, Collins GP, Peniket A. Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy. Eur J Haematol 2020; 105:476-483. [PMID: 32544294 PMCID: PMC7323336 DOI: 10.1111/ejh.13469] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2020] [Revised: 06/10/2020] [Accepted: 06/10/2020] [Indexed: 02/06/2023]
Abstract
OBJECTIVES We sought to characterise the outcomes of patients with haematological malignancy and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in hospital in our regional network of 7 hospitals. METHODS Consecutive hospitalised patients with haematological malignancy and SARS-CoV-2 infection were identified from 01/03/2020 to 06/05/2020. Outcomes were categorised as death, resolved or ongoing. The primary outcome was preliminary case fatality rate (pCFR), defined as the number of cases resulting in death as a proportion of all diagnosed cases. Analysis was primarily descriptive. RESULTS 66 Patients were included, overall pCFR was 51.5%. Patients ≥ 70 years accounted for the majority of hospitalised cases (42, 63%) and fatalities (25, 74%). Mortality was similar between females (52%) and males (51%). Immunosuppressive or cytotoxic treatment within 3 months of the diagnosis of SARS-CoV-2 infection was associated with a significantly higher pCFR of 70%, compared with 28% in those not on active treatment (P = .0013, 2 proportions z test). CONCLUSIONS Mortality rates in patients with haematological malignancy and SARS-CoV-2 infection in hospital are high supporting measures to minimise the risk of infection in this population.
Collapse
Affiliation(s)
- Stephen Booth
- Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - John Willan
- Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.,Department of Haematology, Frimley Health NHS Foundation Trust, Frimley, UK
| | - Henna Wong
- Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Dalia Khan
- Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Rachel Farnell
- Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Alicia Hunter
- Radcliffe Department of Medicine School of Clinical Medicine, University of Oxford, Oxford, UK
| | - Toby Eyre
- Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Harley Katz
- Astrophysics Department, University of Oxford, Oxford, UK
| | - Moez Dungarwalla
- Department of Haematology, Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes, UK
| | - Lucia Chen
- Department of Haematology, Milton Keynes University Hospital NHS Foundation Trust, Milton Keynes, UK
| | - Joe Browning
- Department of Haematology, Buckinghamshire Healthcare NHS Trust, High Wycombe, UK
| | - Paolo Polzella
- Department of Haematology, Buckinghamshire Healthcare NHS Trust, High Wycombe, UK
| | - Nicola Gray
- Department of Haematology, Frimley Health NHS Foundation Trust, Frimley, UK
| | - Pratap Neelakantan
- Department of Haematology, Royal Berkshire Hospital NHS Foundation Trust, Reading, UK
| | - Elissa K Dhillon
- Department of Haematology, Royal Berkshire Hospital NHS Foundation Trust, Reading, UK
| | - David Dutton
- Department of Haematology, Great Western Hospital NHS Foundation Trust, Swindon, UK
| | - Alex Sternberg
- Department of Haematology, Great Western Hospital NHS Foundation Trust, Swindon, UK
| | - Steven Prideaux
- Department of Haematology, Great Western Hospital NHS Foundation Trust, Swindon, UK
| | - Graham P Collins
- Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Andy Peniket
- Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| |
Collapse
|
22
|
Abstract
Despite considerable progress in the treatment of patients with lymphoid malignancies in recent decades, the prognosis of patients with relapsed or refractory lymphomas often remains disappointing. Increasing evidence has established the relevance of epigenetic alterations in the pathogenesis of lymphoid malignancies, and a succession of agents has been evaluated in clinical studies with varying efficacy. In the present review, we outline the importance of epigenetic modifications in lymphoma biology and discuss the published experience with epigenetic modifying agents by lymphoma subtype before considering ongoing clinical studies in this area.
Collapse
Affiliation(s)
- Stephen Booth
- Early Phase Clinical Trials Unit, Department of Oncology, University of Oxford, Oxford, UK
| | - Graham Collins
- Oxford Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| |
Collapse
|
23
|
Tucker D, Morley N, MacLean P, Vandenberghe E, Booth S, Parisi L, Rule S. The 5-year follow-up of a real-world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphoma. Br J Haematol 2020; 192:1035-1038. [PMID: 32445482 DOI: 10.1111/bjh.16739] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2020] [Accepted: 04/21/2020] [Indexed: 11/29/2022]
Abstract
This is a 5-year real-world study of 65 patients treated with ibrutinib for relapsed/refractory mantle cell lymphoma across the UK and Ireland. Ibrutinib was well tolerated with no fatal adverse events. The median progression-free survival and overall survival (OS) was 12 and 18·5 months, respectively. Overall, 80% of patients discontinued treatment, predominantly for progressive disease. On discontinuation, 20% received alternative immunochemotherapy with a median OS of 24 months. Ibrutinib was used as a bridge to transplant in 8% (median OS not reached). These observations are comparable with trial outcomes with encouraging responses to immunochemotherapy at relapse.
Collapse
Affiliation(s)
- David Tucker
- Department of Haematology, Royal Cornwall NHS Hospital Trust, Truro, Cornwall, UK
| | - Nick Morley
- Department of Haematology, Sheffield University Teaching Hospitals NHS Foundation Trust, Sheffield, UK
| | | | | | - Stephen Booth
- Department of Oncology Churchill Hospital Oxford, University of Oxford, Oxford, UK
| | - Lori Parisi
- Department of Research and Development, Janssen Research and Development, Raritan, NJ, USA
| | - Simon Rule
- Plymouth University Hospitals NHS Trust, Plymouth, UK
| |
Collapse
|
24
|
Abstract
Direct oral anticoagulants have become the mainstay of the management of venous thromboembolism and atrial fibrillation, and long-term anticoagulation is indicated for those at high risk of further thrombotic events. This includes patients diagnosed with antiphospholipid syndrome, for whom the 'triple positive' laboratory combination of lupus anticoagulant, β2-glycoprotein-1 and anti-cardiolipin antibodies signify those at greatest risk. Data from meta-analysis and randomised control trials have raised the concern that direct oral anticoagulants may be less effective than vitamin K antagonists for the prevention of thrombosis in patients with thrombotic antiphospholipid syndrome, particularly those with the triple positive profile. This article reviews the diagnosis of thrombotic antiphospholipid syndrome, strategies for testing without interruption of anticoagulation, evidence concerning the safety of direct oral anticoagulants in this setting, and the implications for current investigation and management of unprovoked venous thromboembolism.
Collapse
Affiliation(s)
- Stephen Booth
- Department of Oncology, University of Oxford, Oxford, UK
| | - Kieran Burton
- Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Beverley Hunt
- Haemophilia and Thrombosis Centre, St Thomas' Hospital, London, UK
| | | |
Collapse
|
25
|
De Sousa P, Mansour F, Barbosa M, Booth S, Klein H, Mani A, Nizami M, Von Crease C, Ladas G, Finch J, Asadi N, Beddow E, Mcgonigle N, Anikin V, Begum S, Jordan S, Montero-Fernandez A, Robertus J, Rice A, Nicholson A, Lim E. P1.13-11 An Audit on IASLC Compliance of Lymph Nodes Dissection and Impact on Survival After Surgery for Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
26
|
Djebbari F, Browning JA, Stanton L, Booth S, Hildyard C, Willan J, Bosworth J, Vora SM, Hatton CSR, Collins GP, Eyre TA. Efficacy of R-GCVP in patients with late relapse of diffuse large B-cell lymphoma. Br J Haematol 2019; 186:e191-e195. [PMID: 31222716 DOI: 10.1111/bjh.16071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2019] [Accepted: 05/11/2019] [Indexed: 11/28/2022]
Affiliation(s)
- Faouzi Djebbari
- Department of Pharmacy, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Joseph A Browning
- Department of Haematology, Wycombe General Hospital, High Wycombe, UK
| | - Louise Stanton
- Southampton Clinical Trials Unit, University of Southampton, Southampton General Hospital, Southampton, UK
| | - Stephen Booth
- Department of Haematology, Royal Berkshire Hospital NHS Foundation Trust, Reading, UK
| | | | - John Willan
- Department of Haematology, Wexham Park Hospital, Slough, UK
| | - Jenny Bosworth
- Department of Haematology, Frimley Park Hospital, Frimleyv, UK
| | - Sona M Vora
- Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Chris S R Hatton
- Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Graham P Collins
- Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Toby A Eyre
- Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| |
Collapse
|
27
|
Eyre TA, Kirkwood AA, Wolf J, Hildyard C, Mercer C, Plaschkes H, Griffith J, Fields P, Gunawan A, Oliver R, Booth S, Martinez‐Calle N, McMillan A, Bishton M, Fox CP, Collins GP, Hatton CSR. Stand‐alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R‐CHOP and is associated increased infection‐related toxicity. Br J Haematol 2019; 187:185-194. [DOI: 10.1111/bjh.16070] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2019] [Accepted: 05/11/2019] [Indexed: 11/29/2022]
Affiliation(s)
- Toby A. Eyre
- Department of Haematology Churchill Hospital, Oxford University Hospitals NHS Foundation Trust Oxford UK
| | - Amy A. Kirkwood
- Cancer Research UK & UCL Cancer Trials Centre UCL Cancer Institute, UCL London UK
| | - Julia Wolf
- Department of Haematology Great Western Hospital Swindon UK
| | | | - Carolyn Mercer
- Department of Haematology Churchill Hospital, Oxford University Hospitals NHS Foundation Trust Oxford UK
| | | | - John Griffith
- Department of Haematology Great Western Hospital Swindon UK
| | - Paul Fields
- Department of Haematology Guys and St Thomas’ Hospitals NHS Foundation Trust London UK
| | - Arief Gunawan
- Department of Haematology Guys and St Thomas’ Hospitals NHS Foundation Trust London UK
| | - Rebecca Oliver
- Department of Haematology University Hospitals Bristol NHS Foundation Trust Bristol UK
| | - Stephen Booth
- Department of Haematology Royal Berkshire Hospital NHS Foundation Trust Reading UK
| | - Nicolas Martinez‐Calle
- Department of Clinical Haematology Nottingham University Hospitals NHS Trust Nottingham UK
| | - Andrew McMillan
- Department of Clinical Haematology Nottingham University Hospitals NHS Trust Nottingham UK
| | - Mark Bishton
- Department of Clinical Haematology Nottingham University Hospitals NHS Trust Nottingham UK
| | - Christopher P. Fox
- Department of Clinical Haematology Nottingham University Hospitals NHS Trust Nottingham UK
| | - Graham P. Collins
- Department of Haematology Churchill Hospital, Oxford University Hospitals NHS Foundation Trust Oxford UK
| | - Chris S. R. Hatton
- Department of Haematology Churchill Hospital, Oxford University Hospitals NHS Foundation Trust Oxford UK
| |
Collapse
|
28
|
Follows G, Santarsieri A, Sturgess K, Menne T, Osborne W, Creasey T, Ardeshna K, Behan S, Booth S, Collins G, Cwynarski K, Iyengar S, Jones S, Martinez-Calle N, McKay P, Nagumantry S, O'Mahony D, Rudge J, Shah N, Stafford G, Sternberg A, Uttenthal B, McMillan A. MODIFICATION OF ESCALATED BEACOPP WITH DACARBAZINE / PROCARBAZINE SUBSTITUTION REDUCES RED CELL TRANSFUSION REQUIREMENTS AND MAY SHORTEN TIME TO MENSTRUAL PERIOD RECOVERY. Hematol Oncol 2019. [DOI: 10.1002/hon.168_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- G. Follows
- Haematology; Cambridge University Hospitals NHSFT; Cambridge United Kingdom
| | - A. Santarsieri
- Haematology; Cambridge University Hospitals NHSFT; Cambridge United Kingdom
| | - K. Sturgess
- Haematology; Cambridge University Hospitals NHSFT; Cambridge United Kingdom
| | - T. Menne
- Haematology; Freeman Hospital; Newcastle upon Tyne United Kingdom
| | - W. Osborne
- Haematology; Freeman Hospital; Newcastle upon Tyne United Kingdom
| | - T. Creasey
- Haematology; Freeman Hospital; Newcastle upon Tyne United Kingdom
| | - K.M. Ardeshna
- Haematology; University College London Hospital; London United Kingdom
| | - S. Behan
- Haematology; Cambridge University Hospitals NHSFT; Cambridge United Kingdom
| | - S. Booth
- Haematology; Royal Berkshire NHS Foundation Trust; Reading United Kingdom
| | - G. Collins
- Haematology; Oxford University Hospitals NHSFT; Oxford United Kingdom
| | - K. Cwynarski
- Haematology; University College London Hospital; London United Kingdom
| | - S. Iyengar
- Haematology; The Royal Marsden; London United Kingdom
| | - S. Jones
- Haematology; Sherwood Forest Hospitals; Sutton in Ashfield United Kingdom
| | - N. Martinez-Calle
- Haematology; Nottingham University Hospital NHS Trust; Nottingham United Kingdom
| | - P. McKay
- Haematology; Beatson West of Scotland Cancer Centre; Glasgow United Kingdom
| | - S.K. Nagumantry
- Haematology; Peterborough City Hospital; Peterborough United Kingdom
| | - D. O'Mahony
- Haematology; Cork University Hospital; Wilton Republic of Ireland
| | - J.F. Rudge
- Department of Earth Sciences; University of Cambridge.; Cambridge United Kingdom
| | - N. Shah
- Haematology; Norfolk and Norwich University Hospitals; Norwich United Kingdom
| | - G. Stafford
- Haematology; Cambridge University Hospitals NHSFT; Cambridge United Kingdom
| | - A. Sternberg
- Haematology; Great Western Hospital NHS Foundation Trust; Swindon United Kingdom
| | - B. Uttenthal
- Haematology; Cambridge University Hospitals NHSFT; Cambridge United Kingdom
| | - A. McMillan
- Haematology; Nottingham University Hospital NHS Trust; Nottingham United Kingdom
| |
Collapse
|
29
|
Eyre TA, Martinez-Calle N, Hildyard C, Eyre DW, Plaschkes H, Griffith J, Wolf J, Fields P, Gunawan A, Oliver R, Djebbari F, Booth S, McMillan A, Fox CP, Bishton MJ, Collins GP, Hatton CSR. Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly diffuse large B-cell lymphoma patients treated with curative intent: no difference in cumulative incidence of relapse comparing patients by age. J Intern Med 2019; 285:681-692. [PMID: 30811713 DOI: 10.1111/joim.12889] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
BACKGROUND The increasing incidence of diffuse large B-cell lymphoma (DLBCL) in ageing populations places a significant burden on healthcare systems. Co-morbidity, frailty, and reduced organ and physiological reserve contribute to treatment-related complications. The optimal dose intensity of R-CHOP to optimize outcome across different ages with variable frailty and comorbidity burden is unclear. OBJECTIVES AND METHODS We examined the influence of intended (IDI) and relative (RDI) dose intensity of the combination of cyclophosphamide and doxorubicin, age and comorbidity on outcomes for DLBCL patients ≥70 years in a representative, consecutive cohort across eight UK centres (2009-2018). We determined predictors of survival using multivariable Cox regression, and predictors of recurrence before death using competing risks regression. RESULTS Porgression-free survival (PFS) and overall survival (OS) were significantly inferior in patients ≥80 vs. 70-79 years (P < 0.001). In contrast, 2-year cumulative relapse incidence, when accounting for non-relapse mortality as a competing risk, was no different between 70-79 vs. ≥80 years (P = 0.27) or comorbidity status (CIRS-G: 0-6 vs. >6) (P = 0.27). In 70-79 years, patients with an IDI ≥80% had a significantly improved PFS and OS (P < 0.001) compared to IDI < 80%. Conversely, in patients ≥80 years, there was no difference in PFS (P = 0.88) or OS (P = 0.75) according to IDI <80% vs. ≥80%. On multivariable analysis, when comparing by age, there was a significantly higher cumulative relapse rate for patients aged 70-79 years with an IDI <80% (vs. >80%) (P = 0.04) but not for patients ≥80 years comparing IDI (P = 0.32). CONCLUSION 'R-mini-CHOP' provides adequate lymphoma-specific disease control and represents a reasonable treatment option in elderly patients ≥80 years aiming for cure.
Collapse
Affiliation(s)
- T A Eyre
- Department of Haematology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - N Martinez-Calle
- Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - C Hildyard
- Department of Haematology, Milton Keynes Hospital, Milton Keynes, UK
| | - D W Eyre
- Nuffield Department of Medicine, University of Oxford, Oxford, UK.,Big Data Institute, University of Oxford, Oxford, UK
| | - H Plaschkes
- Oxford University Medical School, Oxford, UK
| | - J Griffith
- Department of Haematology, Great Western Hospital, Swindon, UK
| | - J Wolf
- Department of Haematology, Great Western Hospital, Swindon, UK
| | - P Fields
- Department of Haematology, Guys and St Thomas' Hospitals NHS Foundation Trust, London, UK
| | - A Gunawan
- Department of Haematology, Guys and St Thomas' Hospitals NHS Foundation Trust, London, UK
| | - R Oliver
- Department of Haematology, University Hospitals Bristol NHS Foundation Trust, Bristol, UK
| | - F Djebbari
- Department of Cancer Pharmacy, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - S Booth
- Department of Haematology, Royal Berkshire Hospital NHS Foundation Trust, Reading, UK
| | - A McMillan
- Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - C P Fox
- Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - M J Bishton
- Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - G P Collins
- Department of Haematology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - C S R Hatton
- Department of Haematology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| |
Collapse
|
30
|
Eyre TA, Martinez-Calle N, Hildyard C, Eyre DW, Plaschkes H, Griffith J, Wolf J, Fields PA, Gunawan A, Oliver R, Booth S, McMillan A, Fox CP, Bishton M, Collins GP, Hatton CSR. Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOP. Br J Haematol 2019; 186:e94-e98. [PMID: 31020646 DOI: 10.1111/bjh.15927] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Toby A Eyre
- Department of Haematology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Nicolas Martinez-Calle
- Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | | | - David W Eyre
- Nuffield Department of Medicine, University of Oxford, Oxford, UK.,Big Data Institute, University of Oxford, Oxford, UK
| | | | - John Griffith
- Department of Haematology, Great Western Hospital, Swindon, UK
| | - Julia Wolf
- Department of Haematology, Great Western Hospital, Swindon, UK
| | - Paul A Fields
- Department of Haematology, Guys and St, Thomas' Hospitals NHS Foundation Trust, London, UK
| | - Arief Gunawan
- Department of Haematology, Guys and St, Thomas' Hospitals NHS Foundation Trust, London, UK
| | - Rebecca Oliver
- Department of Haematology, University Hospitals Bristol NHS Foundation Trust, Bristol, UK
| | - Stephen Booth
- Department of Haematology, Royal Berkshire Hospital NHS Foundation Trust, Reading, UK
| | - Andrew McMillan
- Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - Christopher P Fox
- Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - Mark Bishton
- Department of Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - Graham P Collins
- Department of Haematology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Chris S R Hatton
- Department of Haematology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| |
Collapse
|
31
|
Booth S, Price E, Walker E. Fluctuation, invisibility, fatigue - the barriers to maintaining employment with systemic lupus erythematosus: results of an online survey. Lupus 2019; 27:2284-2291. [PMID: 30451638 PMCID: PMC6247450 DOI: 10.1177/0961203318808593] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
Objectives Systemic lupus erythematosus (SLE) is associated with high levels of workplace disability and unemployment. The objective of this study was to understand the reasons for this and to describe the barriers and facilitators of employment identified by people with SLE to develop appropriate solutions. Unemployment, as well as unsuitable work, has adverse health outcomes. Methods Adults with SLE completed a UK-specific online survey, through the LUPUS UK website, designed to find out more about the difficulties and successes that people with SLE have in maintaining employment. The survey was predominantly qualitative, to understand participants’ employment experiences to generate possible solutions. Results Three hundred and ninety-three people gave detailed responses to the survey within eight weeks. Every respondent reported a detrimental effect of SLE on their ability to work: 40.45% had left employment because of it. The themes of concern to respondents were unambiguous: (i) the difficulties of working (and career damage) with SLE, (ii) fear and anxiety overshadowing work/family life, (iii) the greater potential to remain in some employment or stay in full employment when modifications of work pattern and support from management and colleagues were available. SLE-related fatigue, its invisibility and fluctuating nature were felt to be the main barriers to maintaining employment. Numerous respondents could work only part-time and anxiety was high regarding their future ability to continue working. Many had taken substantial pay reductions and refused offered promotions to preserve their health. Distress due to loss of work and the benefits it brings were reported by every respondent who had left work. Conclusion SLE presents specific difficulties for maintaining employment – fatigue, fluctuation and invisibility – not addressed by current anti-discrimination legislation or currently available ‘reasonable adjustments’. This study demonstrates that (i) employment is an important area of concern for people with SLE, (ii) SLE has significant detrimental effects on individuals’ ability to participate and progress in employment, (iii) legislators and employers need information about SLE as invisibility and fluctuation cause hidden problems, and (iv) more data is needed to inform workplace adjustments if individual distress and societal loss of skills are to be addressed.
Collapse
Affiliation(s)
- S Booth
- 1 Cambridge Breathlessness Intervention Service, University of Cambridge, Cambridge, UK
| | - E Price
- 2 Faculty of Health Sciences, University of Hull, Hull, UK
| | - E Walker
- 2 Faculty of Health Sciences, University of Hull, Hull, UK
| |
Collapse
|
32
|
De Sousa P, Mansour F, Barbosa M, Booth S, Klein H, Mani A, Nizami M, Von Crease C, Kyparissopoulos D, Townsend E, Ladas G, Redmond K, Anastasiou N, Finch J, Kuppuswamy M, Asadi N, Beddow E, Mcgonigle N, Anikin V, Begum S, Dusmet M, Jordan S, Montero-Fernandez A, Robertus J, Rice A, Nicholson A, Lim E. An audit on IASLC compliance of lymph nodes dissection and impact on survival after surgery for non-small cell lung cancer. Lung Cancer 2019. [DOI: 10.1016/s0169-5002(19)30201-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
33
|
Ramdharry G, Jones F, Holmes S, James N, Booth S, Reilly M, Hanna M. Neuro-muscular bridges: development of an evidence based selfmanagement resource for people with neuro-muscular diseases. Neuromuscul Disord 2018. [DOI: 10.1016/s0960-8966(18)30412-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
34
|
Scalco R, Morrow J, Booth S, Chatfield S, Godfrey R, Quinlivan R. Misdiagnosis and diagnostic delay in McArdle disease. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
35
|
Scalco R, Manole A, Chatfield S, Booth S, Wigley R, Pattni J, Michalak Z, Desikan M, Godfrey R, Houlden H, Murphy E, Quinlivan R. Exercise profile in patients with SLC2A9 homozygous mutation and a history of exercise induced kidney failure. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
36
|
Abstract
Empirical evidence supports an intimate link between sleep and affective functioning. While the bidirectional relationship between sleep duration and mood is well documented, limited research targets other aspects of affective functioning, such as emotion and emotion regulation, or considers their interrelationships. The present review summarizes research examining the relationship between sleep and emotion, emotion regulation, and mood, and presents a theoretical model representing the relationships between these constructs. Disruptions to sleep and mood may trigger and maintain a negative cascade, leading to more entrenched sleep problems and psychopathology. Given that insufficient sleep is a widespread phenomenon, understanding the interrelationships between sleep and affective functioning has implications for both public health and clinical practice.
Collapse
Affiliation(s)
- Jordan Watling
- a Centre for Sleep Research , University of South Australia , Adelaide , South Australia
| | - Bartholomew Pawlik
- a Centre for Sleep Research , University of South Australia , Adelaide , South Australia.,b School of Psychology , Flinders University , Adelaide , South Australia
| | - Kelly Scott
- a Centre for Sleep Research , University of South Australia , Adelaide , South Australia
| | - Stephen Booth
- a Centre for Sleep Research , University of South Australia , Adelaide , South Australia
| | - Michelle A Short
- a Centre for Sleep Research , University of South Australia , Adelaide , South Australia.,b School of Psychology , Flinders University , Adelaide , South Australia
| |
Collapse
|
37
|
Abstract
This prospective study assessed the results of a custom-made thermoplastic splint for treatment of mallet finger deformity. From April 1999 to April 2000, 42 patients with mallet finger deformity were recruited. All patients were seen within 1 week and treated with a thermoplastic splint custom made by the hand therapy department. The splint was simple to make, easy to fit and suitable for all finger shapes and sizes. It improved the deformity in 30 out of 34 cases, and caused no skin irritation.
Collapse
Affiliation(s)
- S D Richards
- Department of Orthopaedics, Royal Albert Edward Infirmary, Wigan, UK
| | | | | | | | | |
Collapse
|
38
|
Farquhar MC, Ewing G, White P, Burge P, Mahadeva R, Gardener AC, Moore C, Howson S, Booth S, Saunders C, Ling T. P217 Improving care and support in advanced copd – six recommendations from the population-based living with breathlessness study. Thorax 2016. [DOI: 10.1136/thoraxjnl-2016-209333.360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
39
|
Godfrey R, Scalco R, Booth S, Ellerton C, Kahraman A, Chatfield S, Desikan M, Carruthers R, Wakelin A, Pattni J, Quinlivan R. Effect of a multi-disciplinary approach to diagnosis and management for non-lysosomal skeletal muscle glycogen storage disorders. Neuromuscul Disord 2016. [DOI: 10.1016/j.nmd.2016.06.404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
40
|
Thet NT, Alves DR, Bean JE, Booth S, Nzakizwanayo J, Young AER, Jones BV, Jenkins ATA. Prototype Development of the Intelligent Hydrogel Wound Dressing and Its Efficacy in the Detection of Model Pathogenic Wound Biofilms. ACS Appl Mater Interfaces 2016; 8:14909-19. [PMID: 26492095 DOI: 10.1021/acsami.5b07372] [Citation(s) in RCA: 71] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/17/2023]
Abstract
The early detection of wound infection in situ can dramatically improve patient care pathways and clinical outcomes. There is increasing evidence that within an infected wound the main bacterial mode of living is a biofilm: a confluent community of adherent bacteria encased in an extracellular polymeric matrix. Here we have reported the development of a prototype wound dressing, which switches on a fluorescent color when in contact with pathogenic wound biofilms. The dressing is made of a hydrated agarose film in which the fluorescent dye containing vesicles were mixed with agarose and dispersed within the hydrogel matrix. The static and dynamic models of wound biofilms, from clinical strains of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Enterococcus faecalis, were established on nanoporous polycarbonate membrane for 24, 48, and 72 h, and the dressing response to the biofilms on the prototype dressing evaluated. The dressing indicated a clear fluorescent/color response within 4 h, only observed when in contact with biofilms produced by a pathogenic strain. The sensitivity of the dressing to biofilms was dependent on the species and strain types of the bacterial pathogens involved, but a relatively higher response was observed in strains considered good biofilm formers. There was a clear difference in the levels of dressing response, when dressings were tested on bacteria grown in biofilm or in planktonic cultures, suggesting that the level of expression of virulence factors is different depending of the growth mode. Colorimetric detection on wound biofilms of prevalent pathogens (S. aureus, P. aeruginosa, and E. faecalis) is also demonstrated using an ex vivo porcine skin model of burn wound infection.
Collapse
Affiliation(s)
- N T Thet
- Department of Chemistry, University of Bath , Bath BA2 7AY, United Kingdom
| | - D R Alves
- Blond McIndoe Research Foundation, Queen Victoria Hospital , East Grinstead, West Sussex RH19 3DZ, United Kingdom
- Queen Victoria Hospital , East Grinstead, West Sussex RH19 3DZ, United Kingdom
- School of Pharmacy and Biomolecular Sciences, University of Brighton , Brighton BN2 4GJ, United Kingdom
| | - J E Bean
- Blond McIndoe Research Foundation, Queen Victoria Hospital , East Grinstead, West Sussex RH19 3DZ, United Kingdom
| | - S Booth
- Queen Victoria Hospital , East Grinstead, West Sussex RH19 3DZ, United Kingdom
- School of Pharmacy and Biomolecular Sciences, University of Brighton , Brighton BN2 4GJ, United Kingdom
| | - J Nzakizwanayo
- School of Pharmacy and Biomolecular Sciences, University of Brighton , Brighton BN2 4GJ, United Kingdom
| | - A E R Young
- Healing Foundation Children's Burns Research Centre, University Hospitals Bristol NHS Foundation Trust , Bristol BS2 8BJ, United Kingdom
| | - B V Jones
- Queen Victoria Hospital , East Grinstead, West Sussex RH19 3DZ, United Kingdom
- School of Pharmacy and Biomolecular Sciences, University of Brighton , Brighton BN2 4GJ, United Kingdom
| | - A Toby A Jenkins
- Department of Chemistry, University of Bath , Bath BA2 7AY, United Kingdom
| |
Collapse
|
41
|
Chowienczyk S, Javadzadeh S, Booth S, Farquhar M. M4 Association of descriptors of breathlessness with diagnosis, self-reported severity of breathlessness and self-reported distress due to breathlessness in patients with advanced chronic obstructive pulmonary disease or cancer: Abstract M4 Table 1. Thorax 2015. [DOI: 10.1136/thoraxjnl-2015-207770.431] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
42
|
Gardener AC, Farquhar M, Holt Butcher H, Moore C, Ewing G, White P, Howson S, Mahadeva R, Booth S, Burge P, Mendonca S. P49 Higher service use amongst patients with advanced COPD and psychological co-morbidities: Associations with quality of life, co-morbidities and exacerbations: Abstract P49 Table 1. Thorax 2015. [DOI: 10.1136/thoraxjnl-2015-207770.186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
43
|
Javadzadeh S, Chowienczyk S, Booth S, Farquhar M. M5 Comparison of respiratory health-related quality of life in patients with intractable breathlessness due to advanced cancer or advanced COPD: Abstract M5 Table 1. Thorax 2015. [DOI: 10.1136/thoraxjnl-2015-207770.432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
44
|
Farquhar MC, Gardener AC, Moore C, Holt Butcher H, Ewing G, White P, Booth S, Howson S, Mahadeva R. P27 Patients with advanced COPD have unmet care and support needs across clinical settings: how can we identify needs to enable patient-centred care? Thorax 2015. [DOI: 10.1136/thoraxjnl-2015-207770.164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
45
|
Affiliation(s)
- S. Booth
- University Hospital South Manchester; Manchester UK
| | - E. M. Holt
- University Hospital South Manchester; Manchester UK
| | - M. Osbourne
- University Hospital South Manchester; Manchester UK
| |
Collapse
|
46
|
Chin CA, Butcher HH, Spathis A, Ryan R, Johnson M, Pattinson K, Currow D, Banzett R, Yorke J, Clayson H, Macnaughton J, Penfold C, Farquhar M, Booth S. What's trending in breathlessness research? Proceedings from the 8th Annual Meeting of the Breathlessness Research Interest Group. Progress in Palliative Care 2015. [DOI: 10.1179/1743291x15y.0000000005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
47
|
Penfold C, Ewing G, Gilligan D, Mahadeva R, Booth S, Benson J, Burkin J, Howson S, Lovick R, Todd C, Farquhar M. WHAT DO INFORMAL CARERS WANT TO LEARN ABOUT BREATHLESSNESS IN ADVANCED DISEASE AND HOW DO THEY WANT TO LEARN IT? BMJ Support Palliat Care 2015. [DOI: 10.1136/bmjspcare-2014-000838.14] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
48
|
Horsley L, Booth S, Potter P, Clamp A, Jayson G, Hasan J. Clinical Trial Participation and Outcomes in Ovarian Cancer: a Case Control Study. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu338.40] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
49
|
Ryan R, Spathis A, Clow A, Fallon M, Booth S. The biological impact of living with chronic breathlessness – A role for the hypothalamic–pituitary–adrenal axis? Med Hypotheses 2014; 83:232-7. [DOI: 10.1016/j.mehy.2014.04.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2013] [Accepted: 04/02/2014] [Indexed: 10/25/2022]
|
50
|
Lucas V, Booth S. The importance of placebo effects in enhancing palliative care interventions. BMJ Support Palliat Care 2014; 4:212-216. [PMID: 24644208 DOI: 10.1136/bmjspcare-2013-000571] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2013] [Revised: 11/29/2013] [Accepted: 12/28/2013] [Indexed: 11/03/2022]
Abstract
In this narrative review, we examine evidence that may help to explain how placebo effects contribute to the effectiveness of palliative care interventions for the relief of symptoms such as pain, breathlessness and depression, and how they may underlie the impact of complementary therapies. We discuss the different ways of conceptualising placebo phenomena, including the importance of the therapeutic relationship, the context of care and the significance of meaning. There is increasing evidence from neuroscience that the term 'placebo effect' describes a number of phenomena that may explain the effectiveness of therapeutic interventions that affect the perception of symptoms. A greater appreciation of placebo effects emphasises the importance of addressing social, psychological, and spiritual factors with equal rigour. Commissioning bodies, rightly concerned about the evidence base for clinical interventions, need to recognise the multifaceted nature of symptom control measures and to realise that the focus for palliative care research needs to be on the specialty as a complex integrated intervention rather than on a series of individually evaluated measures.
Collapse
Affiliation(s)
- V Lucas
- Garden House Hospice, Letchworth Garden City, UK
| | - S Booth
- Department of Palliative Medicine, University of Cambridge, Cambridge, UK
| |
Collapse
|